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USE OF DYE TO DISTINGUISH SALT AND 
PROTEIN CRYSTALS UNDER 
MICROCRYSTALLIZATION CONDITIONS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims the benefit of priority of U.S. 
Provisional Application No. 601308,698, filed Jul. 30, 2001, 
to Provisional Application Ser. No. 601328,958, filed Oct. 
12, 2001, and to U.S. application Ser. No. 091543,326, filed 
Apr. 5, 2000, which claims benefit of U.S. Provisional 
Application 601128,018, filed Apr. 6, 1999, each of which 
are hereby incorporated in their entirety herein by reference. 
STATEMENT OF GOVERNMENT SUPPORT 
This invention was made with government support under 
NASA Cooperative Agreement No. NCCX-246. The gov- 
ernment may have certain rights in the invention. 
FIELD OF THE INVENTION 
This invention relates generally to the method of using 
detectable agents in crystallization of proteins, wherein the 
detectable agents are preferentially incorporated in the crys- 
tals of proteins or preferentially not incorporated in the 
crystals of proteins such that protein crystals can be readily 
distinguished from crystals of other substances which can 
form under the crystallization conditions, thereby allowing 
rapid and straightforward characterization of crystals and 
evaluation of crystallization conditions used to obtain the 
crystals. 
SUMMARY OF THE INVENTION 
In accordance with the purpose(s) of this invention, as 
embodied and broadly described herein, this invention 
relates to a method of using dyes to facilitate the character- 
ization of protein crystals present in volumes of one micro- 
liter or less. Specifically, it relates to the crystallization of 
proteins from protein solutions containing dyes under con- 
ditions wherein the proteins which crystallize and the other 
components of the protein solutions which crystallize can be 
distinguished from one another on the basis of whether or 
not they form dyed crystals. 
In a first aspect, this invention relates to a method for 
forming a dyed protein crystal including the steps of (1) 
providing a protein solution, wherein the protein solution 
contains at least one dye, which dye is capable of dyeing at 
least a portion of protein crystals formed from the protein 
solution; (2) subjecting the protein solution to environmen- 
tal conditions effective to form protein crystals; and (3) 
detecting the presence of dyed protein crystals, whereby the 
presence of the dyed protein crystals indicates the presence 
of protein crystals. 
In various preferred embodiments of the first aspect of the 
invention, the dye can be chosen from the group consisting 
of methylene blue, methylene green, Izit' and crystal violet. 
In various preferred embodiments of the first aspect of the 
invention, the protein solution is partitioned from the atmo- 
sphere. When the protein solution is partitioned from the 
atmosphere, the partitioning can be done so as to lower the 
rate at which transfer of solvent from the protein solution 
occurs. The protein solution can be partitioned from the 
atmosphere by overlaying the protein solution with an oil. 
The overlaying oil can be selected from the group consisting 
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of paraffin oil, silicone oil or a combination thereof, for 
example, AL's oil' (a 1:l mixture of paraffin and silicone 
oil). The particular mixture of oil selected can be optimized 
for the rate at which transfer of solvent from a protein 
solution occurs when the protein solution is overlayed with 
a particular mixture of oil. Further, the amount of oil 
overlaying the protein solution can be selected so as to 
optimize the rate of solvent transfer from the protein solu- 
tion, in particular, from the protein solution to the oil and 
from the oil to the atmosphere. 
'Reagent is commercially available from Hampton Research, Inc. (www- 
.bamptonresearch.com) 
In various preferred embodiments of the first aspect of the 
invention, the protein solution further includes a component 
selected from the group consisting of salts, buffers, precipi- 
tants, crystallization aids and any combination thereof. The 
component selected can crystallize under the controlled 
environmental conditions to which the protein solution is 
subjected, thereby producing component crystals. The con- 
ditions under which the component crystallizes, can include 
the step or process of adding a precipitate solution. The 
component crystals formed can be undyed component crys- 
tals. 
In various preferred embodiments of the first aspect of the 
invention, any crystals formed in the provided protein solu- 
tion can be detected. If crystals are detected, dyed protein 
crystals can be distinguished from undyed component crys- 
tals. The protein crystals and component crystals can be 
detected by microscopy. 
In a second aspect, this invention relates to a method for 
screening protein crystal growth conditions, including the 
steps of (1) providing a set of at least two protein solutions, 
wherein the protein solutions contain a dye, which is capable 
of dyeing at least a portion of protein crystals formed from 
the protein solution and which does not dye a significant 
portion of component crystals formed from the protein 
solution; (2) subjecting the protein solutions to predeter- 
mined conditions, wherein the environmental conditions to 
which each member of the set of protein solutions is 
subjected is not identical to the environmental conditions to 
which another member of the set is subjected; and (3) 
detecting the presence or non-presence of dyed protein 
crystals and/or undyed component crystals, wherein the 
presence of the dyed protein crystals indicates the formation 
of protein crystals; and the presence of undyed component 
crystals indicates formation of component crystals. 
In various preferred embodiments of the second aspect of 
the invention, the set of protein solutions consists of greater 
than 10,50, 100,250,500, 1000, 1500,2000 or 5000 protein 
solutions. 
In various preferred embodiments of the second aspect of 
the invention, the dye can be chosen from the group con- 
sisting of methylene blue, methylene green, Izit' and crystal 
violet. 
In various preferred embodiments of the second aspect of 
the invention, the protein solutions are partitioned from the 
atmosphere. When the protein solutions are partitioned from 
the atmosphere, the partitioning can be done so as to lower 
the rate at which transfer of solvent from the protein 
solutions occurs. The protein solutions can be partitioned 
from the atmosphere by overlaying the protein solutions 
with an oil. The overlaying oil can be selected from the 
group consisting of paraffin oil, silicone oil or a combination 
thereof, for example, AL's oil' (a 1 : 1 mixture of paraffin and 
silicone oil). The particular mixture of oil selected can be 
optimized for the rate at which transfer of solvent from a 
protein solution occurs when the protein solution is over- 
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layed with a particular mixture of oil. Further, the amount of 
oil overlaying the protein solution can be selected so as to 
optimize the rate of solvent transfer from the protein solu- 
tion, in particular, from the protein solution to the oil and 
from the oil to the atmosphere. 
In various preferred embodiments of the second aspect of 
the invention, the protein solutions further include a com- 
ponent selected from the group consisting of salts, buffers, 
precipitants, crystallization aids and any combination 
thereof. The component selected can crystallize under the 
controlled environmental conditions to which the protein 
solution is subjected, thereby producing component crystals. 
The conditions under which the component crystallizes, can 
include the step or process of adding a precipitate solution. 
The component crystals formed can be undyed component 
crystals. 
In various preferred embodiments of the second aspect of 
the invention, any crystals formed in the provided protein 
solutions can be detected. If crystals are detected, dyed 
protein crystals can be distinguished from undyed compo- 
nent crystals. The protein crystals and component crystals 
can be detected by microscopy. 
In various preferred embodiments of the second aspect of 
the invention, the detection of dyed protein crystals indicates 
a combination of environmental conditions to promote crys- 
tal growth of a protein in the provide protein solutions. 
When dyed proteins are detected, the dyed protein crystals 
can be evaluated in respect to protein crystal quality. Evalu- 
ation of protein crystal quality can include consideration of 
criteria selected from the group consisting of, but not limited 
to, size of crystals, volume of crystals, intensity of coloration 
of crystals by dye, color of coloration of crystals by dye, 
sharpness of crystal edges, and crystal shape. 
In various preferred embodiments of the second aspect of 
the invention, the suitability of crystallization conditions can 
include evaluation of the protein crystal quality of the 
crystals obtained by a certain set of environmental condi- 
tions. 
In a third aspect, this invention relates to a method of 
forming a dyed component crystal including the steps of (1) 
providing a component solution, wherein the component 
solution contains at least one dye, which dye is capable of 
dyeing at least a portion of component crystals formed from 
the component solution; (2) subjecting the component solu- 
tion to environmental conditions effective to form compo- 
nent crystals; and (3) detecting the presence of dyed com- 
ponent crystals, whereby the presence of the dyed 
component crystals indicates the presence of component 
crystals. 
In various preferred embodiments of the third aspect of 
the invention, the component solution is partitioned from the 
atmosphere. When the component solution is partitioned 
from the atmosphere, the partitioning can be done so as to 
lower the rate at which transfer of solvent to or from the 
component solution occurs. The component solution can be 
partitioned from the atmosphere by overlaying the compo- 
nent solution with an oil. The overlaying oil can be selected 
from the group consisting of paraffin oil, silicone oil or a 
combination thereof, for example, AL's oil' (a 1 : 1 mixture 
of paraffin and silicone oil). The particular mixture of oil 
selected can be optimized for the rate at which transfer of 
solvent to or from the component solution occurs when the 
component solution is overlayed with a particular mixture of 
oil. Further, the amount of oil overlaying the component 
solution can be selected so as to optimize the rate of solvent 
transfer to or from the component solution, in particular, 
4 
from the component solution to the oil, or vice versa, and 
from the oil to the atmosphere, or vice versa. 
In various preferred embodiments of the third aspect of 
the invention, the component solution further includes a 
5 protein. The protein selected can crystallize under the con- 
trolled environmental conditions to which the component 
solution is subjected, thereby producing protein crystals. 
The conditions under which the protein crystallizes, can 
include the step or process of adding a precipitate solution. 
In various preferred embodiments of the third aspect of 
the invention, any crystals formed in the provided compo- 
nent solution can be detected. If crystals are detected, 
protein crystals can be distinguished from component crys- 
15 tals on the basis that the protein crystals are undyed protein 
crystals and the component crystals are dyed component 
crystals. The protein crystals and component crystals can be 
detected by microscopy. 
In a fourth aspect, this invention relates to a method for 
20 screening protein crystal growth conditions including the 
steps of (1) providing a set of at least two protein solutions, 
wherein the protein solutions contain a dye, which is capable 
of dyeing at least a portion of component crystals formed 
from the protein solution and which does not dye a signifi- 
25 cant portion of protein crystals formed from the protein 
solution; (2) subjecting the protein solutions to predeter- 
mined conditions, wherein the environmental conditions to 
which each member of the set of protein solutions is 
subjected is not identical to the environmental conditions to 
30 which another member of the set is subjected; and (3) 
detecting the presence or non-presence of undyed protein 
crystals andor dyed component crystals. The presence of the 
undyed protein crystals can indicate the formation of protein 
crystals and the presence of the dyed component crystals can 
35 indicate formation of component crystals. 
In various preferred embodiments of the fourth aspect of 
the invention, the set of protein solutions consists of greater 
than 10,50, 100,250,500, 1000, 1500,2000 or 5000 protein 
solutions. 
In various preferred embodiments of the fourth aspect of 
the invention, the protein solutions are partitioned from the 
atmosphere. When the protein solutions are partitioned from 
the atmosphere, the partitioning can be done so as to lower 
the rate at which transfer of solvent from the protein 
45 solutions occurs. The protein solutions can be partitioned 
from the atmosphere by overlaying the protein solutions 
with an oil. The overlaying oil can be selected from the 
group consisting of paraffin oil, silicone oil or a combination 
thereof, for example, AL's oil' (a 1 : 1 mixture of paraffin and 
50 silicone oil). The particular mixture of oil selected can be 
optimized for the rate at which transfer of solvent from a 
protein solution occurs when the protein solution is over- 
layed with a particular mixture of oil. Further, the amount of 
oil overlaying the protein solution can be selected so as to 
55 optimize the rate of solvent transfer from the protein solu- 
tion, in particular, from the protein solution to the oil and 
from the oil to the atmosphere. The overlaying oil used, or 
the amount of overlaying oil used, to partition any single 
protein solution from the atmosphere can be the same or can 
60 be different than the overlaying oil used to partition any 
other protein solution from the atmosphere. 
In various preferred embodiments of the fourth aspect of 
the invention, the protein solutions can further include a 
component selected from the group consisting of salts, 
65 buffers, precipitants, crystallization aids and any combina- 
tion thereof. The component selected can crystallize under 
the controlled environmental conditions to which the protein 
i o  The protein crystals formed can be dyed protein crystals. 
40 
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solution is subjected, thereby producing component crystals. 
The conditions under which the component crystallizes, can 
include the step or process of adding a precipitate solution. 
The component crystals formed can be dyed component 
crystals. 
In various preferred embodiments of the fourth aspect of 
the invention, crystals formed in the provided protein solu- 
tions can be detected. If crystals are detected, protein crys- 
tals can be distinguished from component crystals on the 
basis that the protein crystals are undyed protein crystals and 
the component crystals are dyed component crystals. The 
protein crystals and component crystals can be detected by 
microscopy. 
In various preferred embodiments of the fourth aspect of 
the invention, the detection of undyed protein crystals indi- 
cates a combination of environmental conditions to promote 
crystal growth of a protein in the provided protein solutions. 
When undyed proteins are detected, the undyed protein 
crystals can be evaluated in respect to protein crystal quality. 
Evaluation of protein crystal quality can include consider- 
ation of criteria selected from the group consisting of, but 
not limited to, size of crystals, volume of crystals, intensity 
of coloration of crystals by dye, color of coloration of 
crystals by dye, sharpness of crystal edges, and crystal 
shape. 
In various preferred embodiments of the fourth aspect of 
the invention, the method of screening the suitability of 
crystallization conditions can include an evaluation of the 
characteristics, numbers or types of component crystals 
formed. 
Additional advantages of the invention will be set forth in 
part in the description, which follows, and in part will be 
obvious from the description, or can be learned by practice 
of the invention. The advantages of the invention will be 
realized and attained by means of the elements and combi- 
nations particularly pointed out in the appended claims. It is 
to be understood that both the foregoing general description 
and the following detailed description are exemplary and 
explanatory only and are not restrictive of the invention, as 
claimed. 
For instance, one advantage provided by one aspect of the 
invention is that the use of the dye to distinguish between 
salt and protein crystals allows rapid screening of crystals 
formed in volumes of less than or equal to approximately 
one microliter to distinguish between those formed of salt 
and those formed of protein. The methods known to the art 
at this time that are used to distinguish between crystals of 
salt and crystals of protein are not able to achieve this result. 
The methods used now: (1) the “crush test” where an 
investigator feels and listens for the sound of salt cracking; 
(2) bombardment of a crystal by x-rays and subsequent 
diffraction pattern analysis; and (3) addition of dye after a 
crystal has been grown and observation of staining; each 
require a crystal of suitable size (0.3 mmx0.3 mmx0.3 mm). 
Crystals grown from volumes of solution less than or equal 
to approximately one microliter are too small for these 
classical methods of analysis. The salt and protein crystals 
formed are too small to crush or to manipulate effectively for 
x-ray bombardment. Also, because the volumes in which the 
crystals are formed are so small, addition of any feasibly 
manipulated volume of dye solution has significant effects 
on the composition of the solution containing the crystals 
and, therefore, significant effects on the crystals therein. 
Furthermore, as use of such small volumes requires that the 
crystals be grown in solutions partitioned from the atmo- 
sphere, generally by an overlaying oil, it is extremely 
difficult to add a dye reagent to protein solutions containing 
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crystals. Inclusion of protein solutions prior to crystal 
growth provides an extremely efficient and simple method to 
screen for protein crystals in volumes of less than one 
microliter. Further, this method reduces the time, cost, and 
skill labor requirements for screening procedures as well as 
lending itself to forms of automated screening, including for 
example, methods of automated screening described in U.S. 
application Ser. No. 091543,326 incorporated herein by 
reference. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The patent or application file contains at least one drawing 
executed in color. Copies of this patent or patent application 
publication with color drawing(s) will be provided by the 
Office upon request and payment of the necessary fee. 
FIG. 1 depicts micrograph images of crystallization trials. 
(FIG. 1A) Izit under oil. (FIG. 1B) NaCl under oil. (FIG. 1C) 
NaCl+dye under oil. (FIG. 1D) Lysozyme under oil. (FIG. 
1E) Lysozyme+dye under oil. (FIG. 1F) Thaumatin under 
oil. (FIG. 1G) Thaumatin+dye under oil. (FIG. 1H) Catalase 
under oil. (FIG. 11) Catalase+dye under oil. (FIG. 1J) 
Trypsin under oil. (FIG. 1K) Trypsin+dye under oil using 
CS15. (FIG. 1L) Trypsin+dye under oil using CS16. In each 
trial, the oil was AL’s oil, 50:50 mixture of paraffin oil and 
silicone oil and the dye was Izit. 
FIG. 2 depicts a lysozyme crystal. This dyed protein 
crystal, at the lower left quadrant of the well, was grown in 
the presence of Izit and has incorporated blue dye. 
FIG. 3 depicts a pepsin crystal. This dyed protein crystal 
was grown in the presence of Izit and has incorporated blue 
dye. 
FIG. 4 depicts a 0-lactoglobulin crystal. This dyed protein 
crystal was grown in the presence of Izit and has incorpo- 
rated blue dye. 
FIG. 5 depicts micrograph images of additional crystal- 
lization trials. FIGS. 5A-5D depict trials conducted using 
Izit wlo any added protein under various screening condi- 
tions. 5E-5F depict trials with added 0-lactoglobulin. FIGS. 
5G-51 depict trials with added myristol transferase. FIG. 5J 
depicts trials with added pepsin. FIGS. 5K and 5L depict 
trials with protein Renac2. FIGS. 5M and 5N depict trials 
with protein ROBl. FIG. 5 0  depicts a trial with protein B10. 
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
The present invention may be understood more readily by 
reference to the following detailed description of preferred 
embodiments of the invention and the Examples included 
therein and to the Figures and their previous and following 
description. 
Before the present compounds, compositions, articles, 
devices, andor methods are disclosed and described, it is to 
be understood that this invention is not limited to specific 
methods of using dye to distinguish between crystals of 
interest and crystals of other character, specific dyes, to 
specific methods of detecting dyed crystals or to particular 
uses of the method disclosed herein, as such may, of course, 
vary. It is also to be understood that the terminology used 
herein is for the purpose of describing particular embodi- 
ments only and is not intended to be limiting. 
As used in the specification and the appended claims, the 
singular forms “a,” “an” and “the” include plural referents 
unless the context clearly dictates otherwise. Thus, for 
example, reference to “a dye” includes mixtures of dyes, 
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reference to “a component” includes mixtures of two or 
more such components, and the like. 
Ranges may be expressed herein as from “about” one 
particular value, andor to “about” another particular value. 
When such a range is expressed, another embodiment 
includes from the one particular value andor to the other 
particular value. Similarly, when values are expressed as 
approximations, by use of the antecedent “about,” it will be 
understood that the particular value forms another embodi- 
ment. It will be further understood that the endpoints of each 
of the ranges are significant both in relation to the other 
endpoint, and independently of the other endpoint. 
In this specification and in the claims, which follow, 
reference will be made to a number of terms, which shall be 
defined to have the following meanings: 
“Optional” or “optionally” means that the subsequently 
described event or circumstance may or may not occur, and 
that the description includes instances where said event or 
circumstance occurs and instances where it does not. For 
example; the phrase “solution optionally containing precipi- 
1) Alanine (A), Serine (S), Threonine (T); 
2) Aspartic acid (D), Glutamic acid (E); 
3) Asparagine (N), Glutamine (Q); 
4) Arginine (R), Lysine (K); 
5 5) Isoleucine (l), Leucine (L), Methionine (M), Valine (V); 
and 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W). 
Further, it will be recognized by one of skill in the art that 
two polynucleotides or polypeptides are said to be “identi- 
cal” if the sequence of nucleotides or amino acid residues in 
i o  the two sequences is the same when aligned for maximum 
correspondence. Optimal alignment of sequences for com- 
parison may be conducted by the local homology algorithm 
of Smith and Waterman Adv. Appl. Math. 2: 482 (1981), by 
the homology alignment algorithm of Needleman and Wun- 
15 sch, J.  Mol. Biol. 48: 443 (1970), by the search for similarity 
method of Pearson and Lipman, Proc. Natl. Acad. Sci. 
U.S.A. 85: 2444 (1 988), by computerized implementations 
of these algorithms (GAP, BESTFIT, FASTA, and TFASTA 
in the Wisconsin Genetics Software Package, Genetics 
20 Computer Group, 575 Science Dr., Madison, Wis.), or by 
tate” means that the solution may or may not contain inspection. 
precipitate and that the description includes both a solution The dye(s) used in the practice of the invention may have 
without precipitate and a solution with a precipitate. no effect on the crystallization of a protein contained in the 
“Detectable,” as used herein, means that the presence or solution. While not being bound by theory, it is contem- 
absence of the molecule or species so described can be 25 plated that the nature of the interaction between the selected 
determined. Alternatively, “detectable,” as used herein, dyes and protein crystals is such that it has no effect on the 
means that the presence or absence of a certain property or structure, stability or growth characteristics of the protein 
characteristic of a molecule or species so described can be crystals of interest. 
determined. For example, a visually detectable characteristic The dye(s) used in the practice of the invention may have 
or property of a species or object, such as a crystal, includes, 30 a negligible effect on the crystallization of proteins con- 
but is not limited to, the intensity, shade and hue of the tained in the solution. For example, protein crystals formed 
species or object. in the presence of the dye may be functionally equivalent in 
“Dye,” as used herein, means an agent which renders respect to their use to determine the structure of the crys- 
another molecule or species detectable by its action on or tallized protein, even though the protein crystals grown in 
association with the other molecule or species. Generally, a 35 the presence of the dye can be distinguished from the protein 
dye will refer to a visually detectable small molecule, which crystals grown in the absence of the dye on the basis of 
interacts with, i.e. stains or colors, another molecule. How- criteria that can be used to evaluate protein crystal quality, 
ever, dye, as used herein, may also mean an agent that acts including the size of crystals, volume of crystals, sharpness 
on another molecule to render it detectable. Dye, as used of crystal edges and crystal shape. 
herein, may also mean an agent, which absorbs or emits 40 The dye(s) used in the practice of the invention may have 
electromagnetic radiation outside of the visible spectrum, a significant effect on the crystallization of proteins con- 
e.g., electromagnetic radiation within the ultraviolet spec- tained in the solution. For example, the protein crystals’ 
trum. growth may be significantly slower when the protein solu- 
“Environment” or “environmental conditions,” as used tion contains the dye or the protein crystals’ growth may be 
herein. means the sum total of all the conditions and 45 simificantlv faster when the motein solution contains the 
elements that make up the surroundings and influence the 
development of any species subject to the environment. The 
environmental conditions of a protein in solution can be 
defined in part by description of a limited number of 
conditions and elements, including but not limited to the 
identity and abundance of atoms or molecules in solution, 
including but not limited to solvents, solutes and precipi- 
tates; other conditions such as but not limited to pH, 
temperature and pressure; and the magnitude and orientation 
of other forces, including but not limited to gravitational 
forces, magnetic forces and electrostatic forces. 
u 
dye. Significant differences in the growth rate of protein 
crystals are those greater than 5, 10, 15,25, 50, 75, 100, 500 
or 1000 fold different. Also, the quality of the crystals may 
be significantly different, as measured by the criteria for 
50 determining a protein crystal’s quality, for example, size of 
crystals, volume of crystals, intensity of coloration of crys- 
tals by dye, color of coloration of crystals by dye, sharpness 
of crystal edges, and crystal shape. 
It will be recognized that under some conditions, for 
55 example, when using Izit dye under high salt conditions and 
at low pH, colored dye crystals can be formed in the absence 
It will be recognized by one of skill in the art that of protein. It will also be recognized that under some 
individual substitutions, deletions or additions which alter, conditions, certain buffer components or salts can crystal 
add or delete a single amino acid or a small percentage of with the dyes used to form colored crystals. Formation of 
amino acids (typically less than 5%, more typically less than 60 such colored dye-only or colored component crystals can be 
1%) in an encoded sequence are conservatively modified detected by screening for the formation of colored crystals 
variations where the alterations result in the substitution of in the absence of any added protein or biomolecule of 
an amino acid with a chemically similar amino acid. Con- interest. Detection of the presence or absence of such 
servative substitution tables providing functionally similar colored crystals under such conditions can be used by one of 
amino acids are well known in the art. The following six 65 skill in the art to evaluate the authenticity of colored crystals 
groups each contain amino acids that are conservative formed under such conditions when protein or the biomol- 
substitutions for one another: ecule of interest is present. 
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Screening protein crystal growth conditions, as is molecules for which there is a need for greater understand- 
described herein, refers broadly to the process of providing ing to solve pressing questions relating to the health and 
at least two protein solutions and subjecting them to different welfare of humankind. While the barrier of insufficient 
conditions and then determining whether or not the condi- crystal quality can often be breached with the application of 
tions allow for the crystallization of proteins included in the sufficient resources, the elucidation of the conditions 
protein solution. The protein solutions, unless otherwise required to produce suitable crystals for x-ray analysis is a 
indicated, contain the same protein species, which is the significant undertaking. The process for determining suit- 
protein of interest. When the protein solutions contain the able conditions generally requires large amounts of both 
same protein of interest, the environmental conditions that a highly skilled labor and highly purified protein. 
given protein solution is subjected to can differ. The protein The application and use of the invention greatly decreases 
solutions can also contain different protein species. When both the quantity of labor and protein required to screen 
the protein species contained in the different protein soh- potential crystallization conditions to obtain effective crys- 
tions differ, the protein species that differ may be either the tallization conditions to provide the suitable high quality 
protein of interest and/or other proteins. The protein of crystals required for x-ray crystallography of biomolecules 
interest, as will be recognized by those of skill in the art, is for the use in structure based drug design and the attendant 
the protein for which the evaluation of protein crystallization l5 benefits thereof. 
conditions is intended. In other words, if an investigator is The significance of the improvement provided by the 
seeking to establish suitable conditions for the crystalliza- invention can be appreciated better in light of what is 
tion of protein X, then protein X is the protein of interest. provided by other state-of-the-art practices relating to x-ray 
The volume of a protein solution used in the method of crystallographic analysis. In particular, the current auto- 
forming dyed or undyed protein crystals or in screening 20 mated processes, the availability of intense x-radiation from 
protein crystallization conditions, as is described herein, can synchrotron sources and improvements in calculating 
be greater than 1, 5, 10, 25, 50, 75, 100, 150, 200, 250, 300, phases, either from molecular replacement or multiple 
400, 500, 600, 700, 800 or 900 pico-, nano-, or micro-liters. anomalous dispersion (MAD) strategies, all appear able to 
The volume of a protein solution used in the method of handle large numbers of crystallized proteins for structure 
forming dyed or undyed protein crystals or in screening 25 determination. However, none of these aforementioned pro- 
protein crystallization conditions, as is described herein, can cesses provide the information necessary, or the means, for 
be less than 5, 10, 25, 50, 75, 100, 150, 200, 250, 300, 400, identifying the proper environmental conditions to form 
500, 600, 700, 800, 900, or 1000 milli-, micro-, nano- or crystals of molecules for growth, diffraction and/or analysis. 
pico-liters. The method of the present invention produces a signifi- 
“Partitioned,” as used herein, refers to the segregation of 3o cant aid in determining the conditions suitable for crystal- 
lizing proteins, thereby greatly facilitating the production of 
suitable protein crystals for structural determination without 
the protein solution from the atmosphere such that the 
transfer of at least one species present in the solution from 
the solution to the atmosphere occurs at a lower rate than 
when the protein solution is not partitioned from the atmo- In particular, the presently disclosed method can facilitate 
sphere. For example, segregation of the protein solution 35 a great reduction in the quantity of protein needed for the 
from the atmosphere by the interposition of a semipermeable screening of large numbers of crystallization conditions and 
membrane, which allows the passage of certain solvent the time required to analyze the outcome of each crystalli- 
molecules, but not others, would partition the protein soh-  zation condition trial. It does so by allowing rapid discrimi- 
tion from the atmosphere. When the protein solution is nation between crystals of protein and crystals of other 
partitioned from the atmosphere, the partitioning may be components present in a crystallization trial in very small 
done so as to lower the rate at which transfer of solvent from 40 volumes. Furthermore, the ease in discrimination between 
the protein solution occurs. The protein solution may be protein crystals of interest and crystals of other materials 
partitioned from the atmosphere by overlaying the protein (e.g., salt, buffer, precipitants) is of particular usefulness 
solution with an oil. The overlaying oil may be selected from when the presently disclosed use of dye to distinguish 
the group consisting of paraffin oil, silicone oil or a com- between protein and salt crystals is applied to pico, nano or 
bination thereof, for example, AL’s oil’ (a 1: 1 mixture of 45 meso scale crystallization trials performed in a microarray or 
paraffin and silicone oil). The particular overlaying oil other micro-device. 
selected may be optimized for the rate at which transfer of In accomplishing the presently disclosed method, the 
solvent from a protein solution occurs when the protein crystallization trials, or necessary parts thereof, can be 
solution is overlayed with a particular mixture of oil. Par- automated. As the method used to characterize the nature of 
affin oil is more restrictive to evaporation of water from the 50 crystals present does not require physical contact between 
overlayed protein solution than either silicone oil or mix- the crystal of interest and a probe or other such element, as 
tures containing paraffin oil and silicone oil. Mixtures of the is required for testing of crystals using conventional means, 
two oils can be used where the rate of evaporation to be the method is more amenable to automation than conven- 
allowed falls between the rate allowed when 100% paraffin tional methods now used to determine that a crystal is a 
oil is used and when 100% silicone oil is used. Mixtures of protein crystal. Embodiments of the method that are auto- 
the two oils having higher paraffin oilisilicone oil ratios are mated are contemplated and provide for the preparation 
more restrictive to transfer of water molecules than those and/or rapid analysis of many samples in high throughput 
mixtures of oil having lower paraffin oilisilicone oil ratios. applications. 
oils, either the Paraffin oil or the silicone oil, can be 5, 10, tallization trials, to conduct trials and to monitor the result- 
15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90 6o ing crystallizations, can include any of those features and 
or 95%. aspects as described in U.S. provisional application 601128, 
The practice of protein crystallization to provide crystals 018 and U.S. utility application Ser. No. 091543,326 both of 
suitable for x-ray diffraction and/or other methods of analy- which are incorporated herein by reference in their entirety. 
sis is often hampered by the difficulty in obtaining crystals However, the automated systems or components thereof 
of sufficient size and quality for analysis. Thus, the most 65 need not include all features described in the previous 
powerful technique currently available for studying the applications. Minimally, a fully automated system need only 
structure of large molecules can often not be applied to include an automated dispensing system to deliver crystal- 
the excessive expenditure of limited resources. 
55 
In mixtures of the two oils, the %(v/v) of either of the two Automated systems to form solutions for preparing crys- 
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lization trial volumes to receptacles, a capability to provide ticular details regarding details of data analysis and deter- 
an environment in which crystals can form under at least mination of whether a biomolecule or a nonbiomolecule 
some conditions, and an ability to detect the presence or (i.e., a protein crystal or a salt crystal) will, of course, vary 
absence of formed crystals. The present invention includes depending on the characteristics of the crystallization con- 
the use of dye to facilitate the detection of crystals. Thus, ditions and the dye being used. Optimization of such par- 
devices of the present invention adapted for automated ticular details are well understood by those of skill in the art 
screening do provide solutions containing the appropriate and would be recognized not to rise to the level of undue 
selected dye and do provide an environment that allows experimentation. 
detection of dyed crystals. In one aspect, provision of that The following examples are put forth so as to provide 
environment is effected by use of wells having clear sides or those of ordinary skill in the art with a complete disclosure 
a clear path for optical detection. As will be recognized by and description of how the compounds, compositions, 
one of skill in the art, such an environment need not provide articles, devices and/or methods claimed herein are made 
such a clear optical path provided other means for detecting and evaluated, and are intended to be purely exemplary of 
the presence of the dyed crystals is provided. Examples of the invention and are not intended to limit the scope of what 
such other means include, but are not limited to, detectors the inventors regard as their invention. Efforts have been 
present within the wells, devices for removal of crystals l5 made to ensure accuracy with respect to numbers (e.g., 
from wells, and detectors as are known in the art that do not amounts, temperature, etc.), but some errors and deviations 
rely upon the presence of a clear optical path, but instead should be accounted for. Unless indicated otherwise, parts 
rely on other physical or chemical properties. are parts by weight, temperature is in O C. or is at ambient 
In particularly useful embodiments contemplated, the temperature, and pressure is at or near atmospheric. 
method can include use of an automated system that dis- 20 
penses the appropriate solutions to form a crystallization 
trial that includes the presence of a dye useful in the practice 
of the invention and overlays the crystallization trial with an 
oil. Such an automated solution can include a microarray for 
crystallization trials, an automated dispensing mechanism 25 
for dispensing the solutions, an automated dispensing 
mechanism for dispensing the overlaying oil, and an auto- Introduction 
mated means for detecting crystal growth. The ability to distinguish between salt and protein crystals 
In particularly useful embodiments contemplated, the has been a problem solved by conventional x-ray crystal- 
method can encompass use of an analysis station that detects 3o lographers in a variety of methods. Those methods include 
the color of crystals in samples that are provided to the the “crush” test whereby a crystal is crushed and determined 
analysis station in an automated fashion. As will be recog- to be salt if it makes a cracking sound. A second method 
nized by those of ordinary skill in the art, detection of crystal involves placing the crystal in a x-ray beam and looking for 
color can include the monitoring and detection of selected diffraction resolution. A third method includes the addition 
portions of the spectra of electromagnetic radiation that are of a dye composed of methylene blue under the commercial 
absorbed, reflected or transmitted by a crystal, whereby 35 name of Izit to the volume containing a crystal. Theoreti- 
detection of said selected portions of the spectra are indica- cally, a crystal of protein contains large channels of solvent 
tive of a color. and will readily uptake the dye, while a crystal of salt is so 
Such automated methods can further include the sorting well packed that the dye will not be taken up into the salt 
of crystals in regard to their determined characteristics. Such crystal. Each of these methods has their pros and cons. The 
sorting can be of a physical nature (Le., the samples con- 40 crush test con is readily apparent, crush your protein crystal 
taining the crystals are segregated according to the nature of and you’re back to the starting point. Mounting crystals and 
crystals contained therein) or can be of an informational shooting to ascertain their ability to diffract takes a signifi- 
nature (Le., the identity of samples containing crystals of a cant amounts of time and effort. The addition of dye to stain 
particular nature andor the location of crystals of a particu- protein crystals is clearly useful, even if not 100% accurate. 
lar nature within a sample are recorded). 45 However, the addition of dye to stain crystals resulting from 
Such automated methods can also include determination a crystallization trial cannot be easily used under certain 
of the number of crystals or objects of specified character or circumstances, particularly those circumstances where small 
identity within a given sample, set of samples or other volumes are required. 
groups. Further, the number and identity relating to obtained The process for high through put screening for protein 
crystals can also be used as a descriptor of conditions used 5o crystallization conditions has been miniaturized which thus 
to obtain crystals. For example, the total number of biomol- improves efficiency, but results in the growth of unmanage- 
ecule crystals obtained andor the fraction of crystals ably small crystals. The crystals are too small for either the 
obtained that are biomolecule crystals can be used to crush test or x-ray analysis, due to difficulty in handling, 
describe results obtained using specific sets of conditions indeed, even addition of dye to the small volumes and to the 
that can be used to form crystals of a specified character. small crystals is difficult. A simple solution to the problem, 
The automated method can monitor samples or crystals 55 the scaling up of various trials to determine if crystals were 
within samples. The automated method can operate in salt or protein, results in the creation of a bottleneck for high 
response to a predetermined program. The predetermined flux structure determination projects, thus negating one of 
program can include input or instructions from the user. the primary advantages sought in the miniaturization of the 
Input or instructions can be provided prior to the screening screening process. 
process or can be provided during the screening process 6o Herein, an alternative method of discriminating between 
either in response to queries generated by the predetermined protein and salt crystals is disclosed. As described in this 
program or by the initiative of the user. example for the purpose of illustration, it includes the 
Data obtained from the method can include images and addition of a blue dye to crystallization trials of approxi- 
data sets representing images or data derived from both mately one microliter or lower volumes under paraffin oil as 
images or selected portions of images. Images can be 65 an aid to the detection and the characterization of protein 
acquired automatically, with user action or with a combina- crystals andor the characterization of crystals as protein 
tion of both automated and non-automated processes. Par- crystals. 
EXAMPLE ONE 
Crystallization of Selected Proteins from Protein 
Solutions Containing Izit 
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Materials and Methods: the crystallized Izit form distinctive networks of blue fibers 
white lysozyme (Boehringer Mannheim, 1243004), 30 presented that suggests that other crystalline forms of Izit or 
mgiml in 0.1 M sodium acetate (PH 4.7); thaumatin (Sigma, dyed crystals of component(s) can occur. In particular, it is 
T7638), 30 mg/ml in 100 mM Tris-HC1 (PH 6.5); bovine 5 noted that sodium thiocyanate might form dyed crystals 
catalase (Sigma, C40), 30 mg/ml in 50 mM HEPES (pH under particular conditions,) 
7.0); cellulase from Tviride (Sigma, C40), 40 mgiml in 100 
mg/ml in 25 m~ HEPES ( P ~  7.01, 10 m~ CaC1,, 10 mg/ml samples tested did not interfere with crystal formation, and 
benzamidin Hc-1; porcine pepsin (sigma, p6887), 60 mg/ml furthermore, resulted in the production of colored protein 
in 100 mM cacodylate buffer (pH 6.5), 0.2 M Ca acetate; crystals, i.e. the dye was taken up by the protein crystals 
equine serum albumin (Sigma, A3434), 50 mg/ml in 50 mM (Table 1; FIG. 1). For each test protein, equal volumes of 
sodium acetate (pH 5.5); Bacillus lichenformis a-amylase sample and crystallization buffer were mixed. These crys- 
(Sigma, A4551), 25 Wiml in 50 mM cacodylate buffer (PH tallization samples were either taken as is, "neat," or Izit was 
The proteins screened in this example were: hen egg or sea urchin crystals. (Note: in Example Three, evidence is 
mM Tris-HCl (pH 8.5); bovine trypsin (Sigma, T8253), 60 For most proteins, the addition Of dye to the protein 
6.75), mM CaC1~; 
mgiml in loo mM 
O-amylase (Sigma, A7130), 
(PH 7.5); bovine O-lactoglobulin 
15 added at a ratio of 1:30, 1:60, or 1:100 in respect to the 
crystallization sample volume, After preparation ofthe crys- 
(Sigma' L3908)' lo mgiml in loo mM Tris-HC1 (pH 6'5)' tallization samples, the samples were deposited into the 
Precipitants were prepared using reagents from Sigma or 
H~~~~~~ ~ ~ ~ ~ ~ ~ h ,  paraffin oil and ~~i~ were purchased crystallization chambers as described in the Materials and 
from Hampton Research. Izit is a commercial preparation of Methods section. Crystal trial samples were then covered 
methylene blue dye, a planar aromatic dye with a molecular 2o with 40 p1 of Paraffin oil and the experiments ~oni tored  for 
weight of 319 daltons. Crystallization trials were performed the formation of protein crystals. Seven out of ten test 
in Labsystems 384 clinical plates under 40 pl of paraffin oil. proteins crystallized in the absence of dye, specifically, 
Crystallization buffers used for: lysozyme (1 00 mM sodium lysozyme, thaumatin, cellulase, pepsin, trypsin, equine 
acetate (PH 4.71, 7% NaC1); thaumatin (1.5 M sodium serum albumin and catalyse crystals formed in the absence 
potassium 
Research), loo mM Tris (PH 8.5), '% 
(Crysta1 screen 36 (Hampton 25 ofthe blue dye, Each of these test proteins also crystallized 
in the presence of dye, but crystallization of only four 
in crysta1s, specifically, lysozyme, 
thaumatin, trypsin and equine Serum albumin. Equine Serum 
cellulase 
(1.4 M ammonium sulfate); trypsin (Crystal Screens 4, 15, 
16, 20, 28,30, 31 (Hampton Research), namely for, (4) 0.1 
M Tris-HCl (PH 8,5), 2.0 M ammonium sulfate; (1 5) 0.2 M 
ammonium sulfate, 0.1 M sodium cacodylate (PH 6.5), 30% 3o albumin displayed Phase changes in the absence and Pres- 
pEG8000; (16) 0.1 M HEpES (pH7.5), 1.5 M lithium sulfate ence of dye. Crystallization of cellulase resulted in small flat 
monohydrate; (20) 0.2 M ammonium sulfate, 0.1 M sodium square plates that appeared to display staining intensity, but 
acetate trihydrate (pH 4.6), 25% PEG4000; (28) 0.2 M it was not possible to definitively characterize the cellulase 
sodium acetate trihYdrate, 0.1 M Sodium cacodylate (PH crystals as blue due to the thinness of the resultant crystals 
PEG8000;(31) o.2 ammonium 30% PEG4000; 35 ground. The color of cellulase crystals was similar to back- 
pepsin, '% equine Serum 2.0 ground hence it was not evident if these crystals absorbed 
the dye. In addition, characterization of the cellulase crystals ammonium sulfate; a-amylase, 1 N NaOH; 0-amylase, 0.17 
M ammonium sulfate. intensity due to unincorporated dye present in each sample 
Crystallization trials were initiated by mixing equal por- 40 was similar for each protein tested, The amount of dye 
incorporated into the protein crystals, and therefore the tions of protein and precipitant solutions prior to depositing a 0.5 pl protein solution drop in the bottom of a crystalli- 
6.51, 30% PEG8000; (30) 0.2 M ammonium sulfate, 30% and the resulting similarity of the coloration to the back- 
ammonium 5% O-lactoglobulin, 2'o was further complicated by their small size, The background 
zation chamber, Protein solutions were then covered with 40 
p1 of paraffin oil, The crystallization chambers were left 
unsealed to incubate at 20" C, Crystal growth was monitored 45 
intensity Of 
tration Of dye used and the number and size Of the crysta1s 
Of and 
depended On the 
l). The reason(s) for the 
daily. pepsin to form crystals in the presence of Izit are unknown. 
It is reasonable to postulate that the failure of catalase and 
Results pepsin crystals to form in the presence of Izit is only isolated 
The dye added to, and present in, the protein solutions of to the single set of conditions used in this trial. AS evidenced 
the nanoliter volume crystallization trials conducted under 50 by the results when attempting to crystallize trypsin, alter- 
oil did not appear to diffuse into the paraffin oil. The dye did ation of the environmental conditions to which a protein 
not stain salt crystals formed during the trials, nor did the solution is subjected can effect changes in the incorporation 
presence of the dye interfere with salt crystal formation. As of dye into a protein crystal. 
a further control, a 0.5 pl drop of undiluted Izit under 40 pl The addition of blue dye to micro and even nanO crys- 
Of paraffin Or to 55 tallization trials under oil, or in a miniaturized crystallization 
incubate at 2oo c. After 72 hours the dye did not appear to condition screening device, such as a microarray, will pro- 
have diffused into the surrounding oils. Even after evapo- vide significant savings in material, time and money, In large ration of the Al's oil, the blue dye remained in place. As 
three of these, crystallization trials were initiated with the 60 of conditions, are protein crystals, without having to repli- 
addition of ~~i~ in quantities of 1 part per 30 parts solution, cate the specific set of conditions on a larger scale, thereby 
1 part per 60 parts solution, and 1 part per 100 parts negating much of the initial benefit of miniaturization. While 
so~utions, Crystals of NaCl were formed under oil in both this improved method of screening crystallization conditions 
the absence and the presence of Izit. In none of the trials, is by no means a replacement for growing suitable sized 
under any of the dilutions tested, did the blue dye enter, and 65 crystals for analysis, it offers a significant improvement to 
thereby color, the salt crystals. As reported, Izit itself will the process of determining appropriate conditions to grow 
crystallize under conditions of high salt. When this occurs, the suitable sized crystals required. 
(Hampton Research) Oil was 
further controls, four 0.5 samples of saturated NaCl part, the savings from the to determine that 
solution were deposited into four separate containers, In crysta1s formed in a miniaturized system, under a specific set 
US 7,250,305 B2 
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EXAMPLE TWO 
Screening Crystallization Conditions for 
Crystallization of Selected Proteins from Protein 
Solutions Containing Izit 
Introduction 
The blue dye Izit facilitated the screening of crystalliza- 
tion conditions suitable for producing crystals of lysozyme, 
pepsin and 0-lactoglobulin. The experimental design used in 
conjunction with the ability to detect nano-scale crystals, 
facilitated by the use of the dye, allowed 450 different sets 
of conditions to be screened. This set of trials, performed in 
duplicate and systematically screening 10 variables, con- 
sumed only a few micrograms of protein. Each crystalliza- 
tion variable was represented by several implementations. 
For example, the variable organic precipitant was repre- 
sented by five levels: 1,2-methy1-2,4-pentanediol (MPD); 2, 
polyethylene glycol 400 (PEG400); 3, PEG2000; 4, 
PEG4000; and 5, PEG8000. This is in stark contrast to 
classical approaches normally used in crystallography that 
use tens of milligrams of protein to screen approximately 
2 4 4 8  sets of conditions. The ease and economy in which 
protein crystallization conditions can be screened using 
these disclosed methods allows a thorough sampling of 
crystallization parameters for any given protein. This allows 
an investigator to readily identify conditions optimal for 
crystallization and can be used to determine conditions 
suitable for the growth of protein crystals of suitable size and 
quality for analysis and characterization. 
Materials and Methods: 
The proteins used as test proteins for this example were: 
hen egg white lysozyme (Boehringer Mannheim, 1243004), 
30 mgiml in 0.1 M sodium acetate (PH 4.7); porcine pepsin 
(Sigma, P6887), 60 mgiml in 100 mM cacodylate buffer (pH 
6.5), 0.2 M Ca acetate; bovine 0-lactoglobulin (Sigma, 
L3908), 10 mgiml in 100 mM Tris-HC1 (pH 6.5). The 
concentrations and buffer solutions used for the nano crys- 
tallization screen are identical to those used in the 0.5 pl 
scale experiments described earlier. Prior to the initiation of 
the nano crystallization screen IZIT was added to each 
sample using a dilution of 1 part dye to 19 parts protein 
Paraffin oil and Izit were purchased from Hampton 
Research. Nanoliter crystallization screens were initiated by 
deploying various ratios of protein sample containing blue 
dye and crystallization buffer (described in Appendix One) 
into a chamber and then overlaying with 40 pl of Al's oil. 
The final volume of the experiments were 80 nl. The ratio of 
protein to precipitating buffer was either 1 :2, 1 : 1, or 2: 1. The 
exact composition of each of the 450 recipes used is 
recorded in the table of screen conditions (Appendix One). 
The pH of the recipes can be calculated using the Hender- 
son-Hasselback equation. Unless otherwise indicated, the 
buffer components included in the crystallization trial con- 
dition recipes are the base (HEPES and MES). MPD and 
0-OG are 2-methyl-2,4-pentanediol and N-octyl-0-d-glu- 
ocpyranoside. PEG400, PEG2K, PEG4000 and PEG XK are 
polyethylene glycols of indicated sizeimass as is known to 
those of skill in the art. 
The experimental nanoliter crystallization volumes were 
sealed during the trials. Data were collected four days after 
the initiation of the experiment and recorded. The results 
were scored by visual inspection. 
Crystallization trials were conducted using the precipitant 
solutions described in Appendix one at the ratios indicated. 
450 trial conditions, repeated in duplicate, were tested for 
each of the proteins. The total volume for each trial protein 
solution was 80 nanoliters at the beginning of the trial. Each 
(viv) . 
5 
10 
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volume of protein solution was overlayed with 40 pl ofAl's 
oil. The crystallization chambers were sealed and left to 
incubate at 4" C. and 20" C. Crystal growth was recorded on 
the fourth day. 
Results 
Conditions which promoted crystallization for each of the 
three proteins tested were identified. The numbers and types 
of crystals formed in the trials can be found in Table 2. For 
each of the three proteins, i.e., lysozyme, pepsin and 0-lac- 
toglobulin, there were 900 total trial results (450 trial 
screening conditions performed in duplicate). Results for 
each trial, i.e., each separate volume of protein solution, 
were analyzed and categorized. These categories include: 
(1) a clear drop, (2) phase separation, (3) precipitate (regular, 
granular), (4) microcrystalsiprecipitate, (5) rosettes or 
spherulites, (6) needles (one-dimensional growth), (7) plates 
(two-dimensional growth), (8) small crystals (three-dimen- 
sional growth of less than 0.2 mm) and (9) crystals (three- 
dimensional growth of greater than 0.2 mm). The categories 
or scores used for the nanoliter crystallization trials were 
adopted from those suggested by Hampton Research. Scor- 
ing of individual experiments to assign each to a category 
was performed by visual inspection. As the titles of the 
categories suggest, the results of each experiment were 
scored based upon presence or absence of detectable species 
and upon the species' morphology. For example, needle-like 
crystals are those appear to have one axis that is very long 
compared to the others, while plates have two axes of 
approximately equivalent size, each significantly larger than 
the third. A three dimensional crystal appears to have growth 
in three dimensions and looks like a brick. For the other 
categories, precipitate looks like sand, while both phase 
separations and rosettes look like mixtures of oil and water. 
The rosettes usually appear to have dense staining in their 
centers. In some instances, there is greater ambiguity as to 
the proper categorical assignment. In addition, the total 
number of trials in which blue crystals formed is also 
indicated. The number of blue crystals is calculated from 
visual inspection of categories 6-9, Le., needles, plates, 
small three dimensional crystals and larger three dimen- 
sional crystals. A representative micrograph of blue crystals 
formed from each of the three proteins screened is shown in 
FIGS. 2 4 .  Specifically: FIG. 2 shows a blue lysozyme 
crystal grown in the presence of Izit using screening con- 
dition 361; FIG. 3 shows a blue pepsin crystal grown in the 
presence of Izit using screening condition 75; and FIG. 4 
shows a blue 0-lactoglobulin crystal grown in the presence 
of Izit using screening condition 213. 
EXAMPLE THREE 
Screening Crystallization Conditions for 
Crystallization of Selected Proteins from Protein 
Solutions Containing Izit and Controls 
Methods similar to those described in Example 2 were 
used to test the method of the invention using additional 
proteins and conditions. FIG. 5 shows micrographs of these 
trials wherein proteins, buffer, conditions and dye were 
varied in character and quantity. Trials were conducted as 
described before and using the noted screening Expt. 
#[Stock] conditions outlined in Appendix One. In the fol- 
lowing example; T1=4" C., T2=15" C., and T3=22" C. 
Crystallization conditions using Izit dye wio any added 
protein were examined. For example, screening conditions 
251 (at T3), 254 (at T3), 285 (at T2), 266 (at T3) and 339 (at 
T3) were conducted. Results from conditions 251,285, 266, 
and 339 are shown in FIGS. 5A, B, C, and D, respectively. 
Condition 254, results not shown, resulted in no observable 
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precipitation or crystallization. Condition 25 1 (FIG. 5A) 
also does not result in any observable crystal formation. 
However, condition 285, which includes acetate buffer at pH 
4.5, 42 mM Ammonium Sulfate, 3.7% MPD, 1% glycerol 
and 2 mM magnesium chloride, and condition 339, which 
includes acetate buffer at pH 4.5,460 mM thiocyanate, 0.8% 
PEG 8000, 0.5% glycerol and 8 mM arginine-HC1, both 
result in apparent crystals. 
Crystallization conditions with various proteins were also 
examined. FIGS. 5E and 5F show results from 0-lactoglo- 
bulin under conditions with phosphate buffer at pH 8 and 
with PEG 400 (at T1) and with phosphate buffer at pH 6, 
PEG 8000, 10% glycerol, 0.008 MArg-HC1 (at T3), respec- 
tively. FIGS. 5G, 5H, and 51 show results from myristol 
transferase under conditions 291 (at T3), 197 (at T2) and 259 
(at T3), respectively. FIG. 5J shows results from pepsin 
under condition 347 (at T3). FIGS. 5K and 5L show results 
from Renac2 under conditions 41 (at T1) and 339 (at T3), 
respectively. FIGS. 5M and 5N show results from Rob1 
under conditions 212 (at T2) and 337 (at T3), respectively. 
FIG. 5 0  shows results from B10 in acetate buffer at pH 4.5, 
with 450 mM thiocyanate, 0.8% PEG 8000, 0.5% glycerol 
and 8 mM arginine HCl (at T3). 
Throughout this application, various publications are ref- 
erenced. The disclosures of these publications in their entire- 
ties are hereby incorporated by reference into this applica- 
tion in order to more fully describe the state of the art to 
which this invention pertains. 
It will be apparent to those skilled in the art that various 
modifications and variations can be made in the present 
invention without departing from the scope or spirit of the 
invention. Other embodiments of the invention will be 
apparent to those skilled in the art from consideration of the 
specification and practice of the invention disclosed herein. 
It is intended that the specification and examples be con- 
sidered as exemplary only, with a true scope and spirit of the 
invention being indicated by the following claims. 
TABLE 1 
Summary of IZIT Crystallization Results 
Protein Neat 1:30 1:60 1:lOO Condition Initial pH 
Lysozyme 
Thaumatin 
Catalase 
Cellulase 
Pepsin 
Equine serum 
albumin 
a-amylase 
fi-amylase 
fi-lactoglobulin 
Trypsin 
Trypsin 
Typsin 
Trypsin 
Trypsin 
Trypsin 
Trypsin 
Xtl 
Xtl 
Xtl 
Xtl 
Xtl 
Pc 
~ 
~ 
~ 
Xtl 
Xtl 
Xtl 
Xtl 
Xtl 
Xtl 
Xtl 
Bxtl 
Bxtl 
Xtl 
~ 
~ 
BPc 
~ 
~ 
~ 
Bxtl 
Xtl 
Bxtl 
Xtl 
Xtl 
Xtl 
Xtl 
Bxtl 
Bxtl 
Xtl 
~ 
~ 
BPc 
~ 
~ 
~ 
Bxtl 
Xtl 
Bxtl 
Xtl 
Xtl 
Xtl 
Xtl 
Bxtl 
Bxtl 
Xtl 
~ 
~ 
BPc 
~ 
~ 
~ 
Bxtl 
Xtl 
Bxtl 
Xtl 
Xtl 
Xtl 
Xtl 
HR 
CS36 
c s 4  
CS15 
CS16 
cs20 
CS28 
CS30 
31 
4.7 
6.5 
8.0 
8.5 
6.5 
5.5 
7.0 
7.5 
6.5 
7.0 
7.0 
7.0 
7.0 
7.0 
7.0 
7.0 
Xtl = crystal, Bxtl = blue crystal, Pc = phase change, BPc = blue phase 
change, neat = absence of Izit in crystallization trial. Condition = the crys- 
tallization buffer used. CS = crystal screen. HR = Hampton Research web 
page http ://www.hamptonresearch.com/. 
18 
TABLE 2A 
Lysozyme 
5 
Score' Frequency 
1 795 
2 58 
3 17 
4 3 
5 1 
10 
15 6 4 
7 1 
8 21 
Number of blue crystals 10 
20 
TABLE 2B 
Pepsin 25 -
Score' Frequency 
30 
35 8 
Number of blue crystals 
591 
24 
30 
9 
0 
25 
164 
57 
2 
TABLE 2C 
40 
J-Lactoglobulin 
Score' Frequency 
45 
1 
2 
3 
4 
5 
6 
7 
50 8 
Number of blue crystals 
807 
58 
8 
13 
1 
5 
7 
1 
5 
55  
1 Score Definitions 
Score Score Descriptor 
1 Clear Drop 
2 Phase Separation 
3 Precipitate (Regular Granular) 
4 MicroCrystals / Precipitate 
5 Rosettes or Spherulites 
6 Needles (1D Growth) 
7 Plates (2D Growth) 
8 
60 
Crystals (3D Growth < 0.2 mm) 
65 9 Crystals (3D Growth > 0.2 mm) 
5 
1 1 4 Mono- 
so- so- Am- so- 2 1 
dium dium 2 3 mo- dium 2 3 4 5 Argi- 3 Gly- 
Expt 1 4 Hydrox- Chlo- Citric Acetic nium Phos- 1 PEG PEG PEG PEG 2 3 nine Beta- cero1 Recipe Protein 
# MES HEPE ide ride Acid Acid Sulfate phate MPD 400 2K 4000 6K MgCI2 CaC12 HCI OG [75% 1 dis- dis- 
(Stock) [OSM] [0 5M] [2M] [2M] [2M] [2M] [2M] [2M] [30%] [30%] [30%] [30%] [30%] [0 2M] [0 2M] [0 5M] [0 5M] w/v] Water Total pensed pensed CI 
v> 
1 62 0 9 0 0 0 0 40 203 0 0 0 0 0 0 0 31 41 614 1000 3 1 
2 0 62 83 0 0 0 0 114 0 0 0 125 0 0 0 31 0 0 585 1000 3 1 
3 62 0 11 48 0 0 0 0 0 0 0 0 240 15 0 0 31 41 552 1000 3 1 
4 0 62 215 0 75 0 0 0 0 0 0 83 0 0 15 31 0 21 499 1000 3 1 
5 62 0 151 0 0 152 0 0 14 0 0 0 0 0 15 0 3 41 566 1000 3 1 
6 62 0 204 0 75 0 0 0 0 83 0 0 0 0 15 0 31 21 509 1000 3 1 
7 62 0 7 121 0 0 0 0 0 0 0 0 11 0 0 0 31 41 729 1000 3 1 
8 62 0 11 40 0 0 0 0 0 0 0 196 0 0 0 0 31 21 641 1000 3 1 
9 0 62 4 115 0 0 0 0 0 0 0 0 127 15 0 31 0 21 626 1000 3 1 
10 62 0 301 0 152 0 0 0 0 13 0 0 0 15 0 0 31 41 385 1000 3 1 
11 0 62 51 0 0 39 0 0 0 0 0 194 0 15 0 0 31 0 608 1000 3 1 
12 0 62 8 0 0 0 149 0 0 13 0 0 0 0 15 0 0 0 753 1000 3 1 
13 62 0 11 182 0 0 0 0 0 0 0 0 16 15 0 0 0 21 694 1000 3 1 
14 0 62 98 0 0 95 0 0 0 105 0 0 0 15 0 0 31 21 573 1000 3 1 
15 0 62 4 0 0 0 182 0 0 0 16 0 0 0 15 0 0 21 701 1000 3 1 
16 0 62 39 0 0 0 0 48 244 0 0 0 0 0 0 31 0 21 556 1000 3 1 
17 0 62 94 0 0 0 0 95 0 0 108 0 0 0 0 0 31 21 591 1000 3 1 
18 62 0 40 0 0 0 0 181 16 0 0 0 0 0 0 0 31 0 670 1000 3 1 
19 62 0 43 0 0 48 0 0 0 0 0 235 0 0 15 0 31 0 566 1000 3 1 
20 0 62 47 0 0 0 0 114 0 0 129 0 0 0 0 31 0 0 617 1000 3 1 
21 62 0 7 0 0 0 0 183 0 16 0 0 0 0 0 0 31 41 661 1000 3 1 
22 0 62 164 0 0 152 0 0 0 0 14 0 0 15 0 31 0 41 522 1000 3 1 
23 62 0 3 0 0 0 96 0 0 106 0 0 0 0 0 31 0 41 661 1000 3 1 
24 62 0 37 0 0 0 0 0 0 197 0 0 0 15 0 31 0 21 598 1000 3 1 
26 62 0 3 40 0 0 0 0 0 0 0 197 0 0 15 0 31 41 611 1000 3 1 
26 62 0 124 0 0 115 0 0 0 0 0 0 127 0 15 0 0 21 536 1000 3 1 
27 62 0 105 0 0 96 0 0 0 0 0 0 106 0 0 0 0 41 590 1000 3 1 
28 62 0 7 96 0 0 0 0 0 106 0 0 0 0 15 31 0 41 642 1000 3 1 
29 62 0 17 0 0 0 0 182 0 0 0 16 0 0 0 31 0 21 672 1000 3 1 
30 0 62 4 116 0 0 0 0 131 0 0 0 0 0 0 0 0 41 647 1000 3 1 
31 0 62 4 0 0 0 181 0 0 0 0 0 16 0 0 0 0 0 738 1000 3 1 
32 62 0 11 48 0 0 0 0 0 237 0 0 0 0 15 0 0 0 628 1000 3 1 
33 62 0 7 0 0 0 115 0 0 0 0 126 0 0 0 0 31 21 639 1000 3 1 
34 0 62 104 0 0 96 0 0 0 0 0 0 106 15 0 0 31 41 546 1000 3 1 
35 0 62 127 0 0 0 0 181 0 0 0 16 0 0 0 0 31 0 584 1000 3 1 
36 0 62 142 0 0 0 0 152 0 13 0 0 0 0 0 0 0 41 590 1000 3 1 
37 62 0 130 0 0 149 0 0 0 0 0 0 13 0 0 0 31 0 615 1000 3 1 
38 0 62 8 0 0 0 118 0 0 0 11 0 0 0 15 31 0 0 756 1000 3 1 
39 0 62 87 0 0 75 0 0 85 0 0 0 0 15 0 0 0 21 655 1000 3 1 
40 0 62 107 0 0 0 0 151 0 0 0 0 13 0 0 31 0 21 616 1000 3 1 
41 0 62 8 0 0 0 151 0 0 13 0 0 0 15 0 0 31 21 700 1000 3 1 
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-continued 
5 
1 1 4 Mono- 
so- so- Am- so- 2 1 
dium dium 2 3 mo- dium 2 3 4 5 Argi- 3 Gly- 
Expt 1 4 Hydrox- Chlo- Citric Acetic nium Phos- 1 PEG PEG PEG PEG 2 3 nine Beta- cero1 Recipe Protein 
# MES HEPE ide ride Acid Acid Sulfate phate MPD 400 2K 4000 6K MgCI2 CaC12 HCI OG [75% 1 dis- dis- 
(Stock) [OSM] [0 5M] [2M] [2M] [2M] [2M] [2M] [2M] [30%] [30%] [30%] [30%] [30%] [0 2M] [0 2M] [0 5M] [0 5M] w/v] Water Total pensed pensed 
42 62 0 7 149 0 0 0 0 0 0 0 13 0 0 15 0 0 0 754 
43 0 62 92 0 31 0 0 0 0 158 0 0 0 0 15 0 31 21 592 
44 0 62 84 0 0 76 0 0 0 84 0 0 0 0 15 0 0 41 638 
45 62 0 11 0 0 0 75 0 0 0 0 0 83 15 0 31 0 21 702 
46 62 0 354 0 152 0 0 0 0 0 0 13 0 0 0 31 0 41 347 
47 0 62 12 0 0 0 48 0 0 0 245 0 0 15 0 0 31 41 546 
48 62 0 164 0 76 0 0 0 0 0 86 0 0 15 0 31 0 41 525 
49 62 0 9 0 0 0 0 32 0 158 0 0 0 0 0 31 0 41 668 
50 62 0 112 0 40 0 0 0 202 0 0 0 0 15 0 31 0 21 518 
51 0 73 151 0 49 0 0 0 0 242 0 0 0 0 0 0 36 0 449 
52 73 0 75 0 30 0 0 0 0 0 150 0 0 0 0 0 36 24 611 
53 73 0 197 0 72 0 0 0 0 0 0 0 79 18 0 0 36 48 477 
54 0 73 193 0 0 185 0 0 0 0 0 16 0 0 18 0 36 0 479 
55 0 73 9 30 0 0 0 0 0 149 0 0 0 0 0 36 0 48 655 
56 0 73 4 49 0 0 0 0 251 0 0 0 0 0 0 36 0 48 537 
57 0 73 9 0 0 0 29 0 0 0 0 0 145 0 18 0 36 0 690 
58 73 0 8 95 0 0 0 0 0 0 108 0 0 0 18 36 0 48 613 
59 73 0 18 0 0 0 0 29 0 0 148 0 0 0 0 0 36 0 696 
60 73 0 223 0 94 0 0 0 106 0 0 0 0 0 18 0 36 24 425 
61 0 73 87 0 30 0 0 0 0 0 0 0 147 0 0 0 0 24 640 
62 0 73 127 0 0 114 0 0 0 10 0 0 0 0 0 0 36 48 591 
63 0 73 4 151 0 0 0 0 0 0 0 13 0 0 0 36 0 48 674 
64 0 73 161 0 49 0 0 0 0 0 0 244 0 0 0 36 0 48 389 
65 73 0 13 188 0 0 0 0 0 16 0 0 0 0 0 0 0 48 652 
66 0 73 9 0 0 0 119 0 0 0 0 130 0 0 0 0 36 48 585 
67 0 73 53 0 0 49 0 0 0 0 249 0 0 18 0 0 0 24 533 
68 0 73 143 0 49 0 0 0 0 0 0 0 246 18 0 0 0 48 423 
69 0 73 4 0 0 0 148 0 0 13 0 0 0 18 0 0 0 0 744 
70 73 0 13 0 0 0 112 0 0 0 0 0 10 0 18 36 0 24 714 
71 73 0 8 149 0 0 0 0 0 0 0 0 13 0 18 0 36 24 678 
72 0 73 49 0 0 0 0 118 0 0 0 129 0 0 0 0 0 24 607 
73 0 73 132 0 40 0 0 0 0 0 0 196 0 18 0 0 36 48 457 
74 0 73 120 0 0 111 0 0 0 0 10 0 0 18 0 0 0 0 669 
75 0 73 4 94 0 0 0 0 0 104 0 0 0 18 0 0 36 24 646 
76 0 73 14 0 0 0 70 0 0 0 0 0 77 0 0 36 0 0 730 
77 73 0 132 0 0 151 0 0 13 0 0 0 0 18 0 0 36 48 529 
78 0 73 116 0 0 112 0 0 0 10 0 0 0 0 18 36 0 24 611 
79 73 0 6 0 0 0 0 118 0 0 0 0 130 0 0 0 0 24 649 
80 73 0 14 0 0 0 0 94 0 0 107 0 0 0 0 0 0 24 689 
81 0 73 9 0 0 0 70 0 79 0 0 0 0 0 0 0 36 0 733 
82 0 73 4 188 0 0 0 0 17 0 0 0 0 18 0 0 0 24 678 
83 73 0 129 0 0 148 0 0 0 0 0 0 13 0 0 36 0 0 601 
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5 
1 1 4 Mono- 
so- so- Am- so- 2 1 
dium dium 2 3 mo- dium 2 3 4 5 Argi- 3 Gly- 
Expt 1 4 Hydrox- Chlo- Citric Acetic nium Phos- 1 PEG PEG PEG PEG 2 3 nine Beta- cero1 Recipe Protein 
# MES HEPE ide ride Acid Acid Sulfate phate MPD 400 2K 4000 6K MgCI2 CaC12 HCI OG [75% 1 dis- dis- 
(Stock) [OSM] [0 5M] [2M] [2M] [2M] [2M] [2M] [2M] [30%] [30%] [30%] [30%] [30%] [0 2M] [0 2M] [0 5M] [0 5M] w/v] Water Total pensed pensed 
84 
85 
86 
87 
88 
89 
90 
91 
92 
93 
94 
95 
96 
97 
98 
99 
100 
101 
102 
103 
104 
105 
106 
107 
108 
109 
110 
111 
112 
113 
114 
115 
116 
117 
118 
119 
120 
121 
122 
123 
124 
125 
0 73 4 0 0 0 39 0 0 0 200 0 0 18 0 0 36 24 605 
0 73 14 30 0 0 0 0 0 149 0 0 0 0 0 36 0 48 650 
73 0 75 0 30 0 0 0 0 0 0 0 147 0 0 0 0 24 651 
73 0 19 0 0 0 0 39 198 0 0 0 0 0 0 0 0 0 671 
73 0 42 0 0 30 0 0 0 0 0 148 0 18 0 36 0 48 604 
0 73 158 0 49 0 0 0 0 0 0 0 242 0 0 36 0 0 442 
73 0 89 0 30 0 0 0 152 0 0 0 0 0 18 36 0 48 553 
0 73 14 119 0 0 0 0 0 0 134 0 0 0 0 0 36 48 576 
73 0 65 0 0 72 0 0 81 0 0 0 0 0 0 0 36 48 625 
0 73 152 0 49 0 0 0 0 0 0 0 244 0 18 36 0 24 403 
0 73 9 29 0 0 0 0 0 145 0 0 0 0 0 0 0 0 744 
73 0 203 0 94 0 0 0 106 0 0 0 0 0 0 0 36 24 463 
73 0 43 0 0 0 0 186 0 0 17 0 0 0 0 0 36 24 620 
0 73 9 0 0 0 117 0 0 0 0 0 129 0 18 36 0 0 618 
0 73 14 0 0 0 148 0 13 0 0 0 0 0 0 0 0 0 753 
73 0 13 0 0 0 49 0 0 246 0 0 0 0 18 36 0 48 516 
73 0 148 0 0 148 0 0 13 0 0 0 0 0 0 36 0 0 582 
0 100 203 0 0 0 0 214 0 19 0 0 0 0 0 0 0 0 464 
0 100 6 167 0 0 0 0 0 0 15 0 0 25 0 50 0 67 570 
0 100 33 0 0 0 0 31 0 0 156 0 0 0 0 50 0 67 554 
0 100 50 0 0 0 0 114 0 0 0 10 0 0 0 0 50 33 643 
100 0 21 0 0 0 0 167 0 0 15 0 0 0 0 0 50 67 580 
0 100 322 0 106 0 0 0 0 0 0 0 117 0 0 0 0 67 289 
100 0 54 0 0 57 0 0 292 0 0 0 0 25 0 0 0 67 405 
0 100 76 0 0 71 0 0 0 78 0 0 0 0 25 0 0 0 649 
100 0 7 0 0 0 0 106 0 0 0 116 0 0 0 50 0 67 555 
100 0 61 0 0 44 0 0 224 0 0 0 0 0 0 0 50 67 454 
100 0 18 0 0 0 135 0 0 0 153 0 0 0 0 50 0 0 544 
0 100 6 0 0 0 31 0 0 0 156 0 0 0 0 0 0 67 641 
100 0 27 0 0 0 0 57 289 0 0 0 0 0 0 0 50 33 443 
100 0 296 0 138 0 0 0 156 0 0 0 0 0 0 0 50 67 194 
100 0 129 0 43 0 0 0 0 0 0 0 216 25 0 50 0 33 403 
100 0 18 0 0 0 167 0 0 0 0 0 15 0 25 50 0 67 559 
100 0 11 114 0 0 0 0 0 0 0 10 0 25 0 50 0 33 655 
100 0 5 104 0 0 0 0 0 115 0 0 0 0 25 0 50 33 567 
0 100 6 218 0 0 0 0 19 0 0 0 0 0 25 0 0 67 565 
0 100 41 0 0 0 0 43 221 0 0 0 0 0 0 50 0 33 511 
100 0 18 0 0 0 136 0 0 0 154 0 0 0 25 50 0 33 483 
100 0 163 0 57 0 0 0 289 0 0 0 0 25 0 50 0 33 282 
100 0 232 0 0 218 0 0 0 0 0 0 19 25 0 0 0 67 339 
100 0 111 0 0 108 0 0 0 0 0 116 0 0 25 0 50 67 426 
0 100 163 0 0 0 0 167 15 0 0 0 0 0 0 50 0 67 438 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
1000 
h) w 3 1 3 1 
3 1 
3 1 
3 1 
3 1 
3 1 
3 1 
3 1 
3 1 
3 1 
3 1 
3 1 
3 1 
3 1 
3 1 
3 1 
2 2 
2 2 
2 2 
2 2 
2 2 
2 2 
2 2 
2 2 
2 2 
2 2 
2 2 
2 2 
2 2 
2 2 
2 2 
2 2 
2 2 
2 2 
2 2 
2 2 
2 2 
2 2 
2 2 
2 2 
2 2 
c 
tA 
4 
N 
ul 
0 
w 
0 
ul 
F? 
h) a 
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5 
1 1 4 Mono- 
so- so- Am- so- 2 1 
dium dium 2 3 mo- dium 2 3 4 5 Argi- 3 Gly- 
Expt 1 4 Hydrox- Chlo- Citric Acetic nium Phos- 1 PEG PEG PEG PEG 2 3 nine Beta- cero1 Recipe Protein 
# MES HEPE ide ride Acid Acid Sulfate phate MPD 400 2K 4000 6K MgCI2 CaC12 HCI OG [75% 1 dis- dis- 
(Stock) [OSM] [0 5M] [2M] [2M] [2M] [2M] [2M] [2M] [30%] [30%] [30%] [30%] [30%] [0 2M] [0 2M] [0 5M] [0 5M] w/v] Water Total pensed pensed 
126 
127 
128 
129 
130 
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134 
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136 
137 
138 
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143 
144 
145 
146 
147 
148 
149 
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151 
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154 
155 
156 
157 
158 
159 
160 
161 
162 
163 
164 
165 
166 
167 
0 100 41 0 0 0 0 43 218 0 0 0 0 0 0 0 50 0 548 
100 0 53 0 0 44 0 0 0 0 224 0 0 25 0 50 0 67 437 
0 100 19 0 0 0 56 0 0 0 287 0 0 25 0 0 0 0 513 
100 0 37 0 0 0 0 116 0 0 0 10 0 0 0 50 0 67 620 
100 0 142 0 57 0 0 0 0 0 292 0 0 0 25 0 50 67 266 
0 100 429 0 138 0 0 0 0 0 0 151 0 25 0 0 50 67 40 
100 0 96 0 31 0 0 0 0 152 0 0 0 25 0 50 0 67 479 
0 100 294 0 103 0 0 0 0 0 117 0 0 0 25 0 50 0 311 
100 0 18 138 0 0 0 0 0 0 156 0 0 0 25 0 0 67 497 
0 100 6 57 0 0 0 0 292 0 0 0 0 0 0 50 0 67 428 
0 100 88 0 0 0 0 214 19 0 0 0 0 0 0 0 0 0 579 
100 0 11 0 0 0 73 0 0 0 0 81 0 25 0 50 0 67 593 
0 100 172 0 0 167 0 0 0 0 15 0 0 0 0 0 50 67 429 
100 0 24 0 0 0 0 216 0 19 0 0 0 0 0 50 0 33 558 
100 0 11 116 0 0 0 0 0 0 0 10 0 25 0 50 0 67 621 
100 0 52 0 0 43 0 0 0 218 0 0 0 25 0 0 50 33 480 
0 100 662 0 216 0 0 0 19 0 0 0 0 0 0 50 0 33 81 
100 0 11 0 0 0 116 0 0 0 10 0 0 25 0 50 0 67 621 
100 0 140 0 0 136 0 0 0 0 0 150 0 0 25 0 50 33 365 
0 100 347 0 114 0 0 0 0 0 0 10 0 0 0 0 50 33 345 
0 100 6 0 0 0 112 0 0 0 0 10 0 25 0 0 50 0 697 
100 0 5 0 0 0 138 0 0 0 0 0 152 0 0 50 0 67 488 
0 100 49 0 0 30 0 0 0 0 0 0 147 0 0 0 0 0 675 
0 100 129 0 0 116 0 0 0 0 0 10 0 25 0 0 0 67 553 
100 0 60 0 0 43 0 0 0 0 219 0 0 0 0 50 0 0 528 
0 62 51 0 0 48 0 0 0 238 0 0 0 0 15 0 31 21 534 
62 0 4 0 0 0 0 40 0 0 202 0 0 0 0 0 31 21 642 
62 0 3 0 0 0 118 0 0 0 0 10 0 0 0 31 0 0 776 
0 62 191 0 0 183 0 0 0 0 16 0 0 15 0 0 0 41 492 
62 0 7 0 0 0 118 0 131 0 0 0 0 0 0 31 0 41 613 
0 62 12 0 0 0 40 0 0 197 0 0 0 0 15 31 0 21 623 
62 0 11 151 0 0 0 0 0 0 0 0 13 15 0 0 0 21 728 
0 62 12 0 0 0 121 0 11 0 0 0 0 15 0 0 31 41 708 
0 62 361 0 121 0 0 0 0 0 11 0 0 0 15 0 31 41 359 
62 0 7 0 0 0 181 0 0 0 0 16 0 15 0 31 0 0 689 
0 62 4 0 0 0 48 0 245 0 0 0 0 0 0 0 0 41 600 
0 62 236 0 75 0 0 0 0 0 0 83 0 0 15 31 0 21 478 
62 0 202 0 75 0 0 0 84 0 0 0 0 15 0 31 0 0 532 
0 62 12 116 0 0 0 0 131 0 0 0 0 0 15 0 0 41 624 
0 62 101 0 32 0 0 0 0 158 0 0 0 0 0 0 31 41 578 
62 0 16 0 0 0 0 31 0 156 0 0 0 0 0 0 0 21 714 
0 62 4 114 0 0 0 0 0 0 0 125 0 0 0 0 31 0 665 
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5 
1 1 4 Mono- 
so- so- Am- so- 2 1 
dium dium 2 3 mo- dium 2 3 4 5 Argi- 3 Gly- 
Expt 1 4 Hydrox- Chlo- Citric Acetic nium Phos- 1 PEG PEG PEG PEG 2 3 nine Beta- cero1 Recipe Protein 
# MES HEPE ide ride Acid Acid Sulfate phate MPD 400 2K 4000 6K MgCI2 CaC12 HCI OG [75% 1 dis- dis- 
(Stock) [OSM] [0 5M] [2M] [2M] [2M] [2M] [2M] [2M] [30%] [30%] [30%] [30%] [30%] [0 2M] [0 2M] [0 5M] [0 5M] w/v] Water Total pensed pensed 
168 
169 
170 
171 
172 
173 
174 
175 
176 
177 
178 
179 
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182 
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185 
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197 
198 
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200 
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204 
205 
206 
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208 
209 
0 62 123 0 0 116 0 0 0 128 0 0 0 0 15 0 0 41 515 
62 0 11 31 0 0 0 0 0 0 158 0 0 0 15 0 31 0 692 
0 62 12 0 0 0 94 0 0 0 0 104 0 15 0 31 0 0 683 
0 62 12 95 0 0 0 0 0 0 0 0 105 15 0 0 31 21 660 
0 62 12 0 0 0 75 0 0 83 0 0 0 0 0 0 0 0 770 
0 62 55 0 0 48 0 0 242 0 0 0 0 15 0 0 31 0 548 
0 62 357 0 119 0 0 0 11 0 0 0 0 0 0 0 0 21 431 
0 62 8 119 0 0 0 0 11 0 0 0 0 15 0 0 31 21 734 
62 0 104 0 48 0 0 0 0 0 0 0 237 0 0 0 31 0 520 
0 62 8 0 0 0 152 0 14 0 0 0 0 0 0 0 31 41 693 
62 0 179 0 75 0 0 0 85 0 0 0 0 0 15 0 0 21 563 
0 62 8 75 0 0 0 0 0 0 84 0 0 15 0 0 31 0 726 
62 0 296 0 149 0 0 0 0 0 0 0 13 15 0 0 31 0 434 
0 62 157 0 0 149 0 0 0 0 0 13 0 0 0 0 31 0 588 
62 0 97 0 40 0 0 0 0 0 0 0 197 0 15 31 0 21 537 
0 62 28 0 0 0 0 31 0 0 0 0 155 0 0 0 31 0 694 
0 62 46 0 0 0 0 40 203 0 0 0 0 0 0 0 31 41 577 
62 0 204 0 95 0 0 0 0 0 0 0 105 15 0 31 0 21 467 
62 0 85 0 0 75 0 0 0 83 0 0 0 0 0 0 31 21 643 
0 62 12 95 0 0 0 0 108 0 0 0 0 0 15 31 0 21 657 
62 0 307 0 116 0 0 0 131 0 0 0 0 0 0 31 0 41 313 
0 62 94 0 0 0 0 96 0 0 0 0 106 0 0 0 0 41 601 
62 0 3 116 0 0 0 0 131 0 0 0 0 0 15 0 0 41 632 
62 0 5 0 0 0 0 75 0 0 85 0 0 0 0 31 0 21 722 
0 62 87 0 0 0 0 121 11 0 0 0 0 0 0 0 0 41 679 
0 62 98 0 0 94 0 0 0 0 107 0 0 0 15 31 0 0 594 
62 0 7 0 0 0 0 181 0 0 0 0 16 0 0 0 31 0 705 
0 62 62 0 0 0 0 152 14 0 0 0 0 0 0 0 0 41 670 
0 62 4 182 0 0 0 0 0 0 0 16 0 15 0 0 0 21 701 
0 62 8 0 0 0 39 0 200 0 0 0 0 0 0 0 0 0 691 
62 0 131 0 0 151 0 0 0 0 0 0 13 0 15 0 0 21 608 
0 62 154 0 48 0 0 0 0 0 0 237 0 0 15 31 0 21 433 
0 62 87 0 0 0 0 121 0 0 0 0 11 0 0 0 0 41 679 
0 73 14 118 0 0 0 0 133 0 0 0 0 0 18 36 0 24 584 
0 73 32 0 0 0 0 72 0 0 0 0 79 0 0 36 0 48 650 
73 0 29 0 0 0 0 95 108 0 0 0 0 0 0 0 0 48 648 
0 73 56 0 0 0 0 49 0 0 0 0 242 0 0 0 0 0 581 
0 73 113 0 39 0 0 0 198 0 0 0 0 18 0 36 0 0 523 
73 0 21 0 0 0 0 49 0 242 0 0 0 0 0 36 0 0 580 
73 0 128 0 0 117 0 0 0 0 0 0 129 18 0 36 0 0 500 
0 73 61 0 0 0 0 149 0 0 0 13 0 0 0 0 0 24 680 
0 73 563 0 185 0 0 0 0 0 0 16 0 0 0 36 0 0 127 
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5 
1 1 4 Mono- 
so- so- Am- so- 2 1 
dium dium 2 3 mo- dium 2 3 4 5 Argi- 3 Gly- 
Expt 1 4 Hydrox- Chlo- Citric Acetic nium Phos- 1 PEG PEG PEG PEG 2 3 nine Beta- cero1 Recipe Protein 
# MES HEPE ide ride Acid Acid Sulfate phate MPD 400 2K 4000 6K MgCI2 CaC12 HCI OG [75% 1 dis- dis- 
(Stock) [OSM] [0 5M] [2M] [2M] [2M] [2M] [2M] [2M] [30%] [30%] [30%] [30%] [30%] [0 2M] [0 2M] [0 5M] [0 5M] w/v] Water Total pensed pensed 
210 
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248 
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73 0 138 0 49 0 0 0 0 0 249 0 0 18 0 0 0 24 448 
0 73 9 185 0 0 0 0 0 0 16 0 0 0 0 0 0 0 717 
0 73 75 0 0 0 0 185 0 0 0 0 16 0 0 0 36 0 615 
0 73 214 0 70 0 0 0 0 0 79 0 0 18 0 36 0 0 510 
73 0 8 186 0 0 0 0 0 0 17 0 0 0 18 36 0 24 638 
0 73 14 0 0 0 111 0 0 10 0 0 0 0 18 0 36 0 739 
0 73 40 0 0 0 0 94 0 0 0 0 104 0 0 0 36 24 628 
73 0 10 0 0 0 0 40 0 0 0 196 0 0 0 0 0 48 633 
0 73 482 0 151 0 0 0 13 0 0 0 0 0 0 0 36 48 215 
73 0 4 0 0 0 0 30 0 0 150 0 0 0 0 36 0 24 683 
73 0 120 0 0 119 0 0 0 0 0 0 131 18 0 0 36 48 454 
73 0 299 0 151 0 0 0 0 0 0 0 13 18 0 0 0 48 398 
0 73 14 30 0 0 0 0 0 0 0 148 0 0 0 36 0 48 651 
73 0 8 0 0 0 95 0 0 0 0 104 0 18 0 0 0 48 653 
73 0 10 0 0 0 0 29 0 0 0 0 145 0 0 0 0 0 744 
0 73 462 0 151 0 0 0 0 0 13 0 0 0 0 36 0 48 216 
73 0 197 0 72 0 0 0 0 0 0 79 0 0 18 0 0 48 514 
0 73 549 0 185 0 0 0 0 16 0 0 0 0 0 0 36 0 141 
0 73 9 0 0 0 185 0 0 0 0 16 0 0 18 0 36 0 663 
0 73 446 0 149 0 0 0 0 0 0 0 13 0 0 36 0 24 259 
0 73 19 0 0 0 0 39 0 0 200 0 0 0 0 36 0 24 606 
73 0 112 0 39 0 0 0 198 0 0 0 0 18 0 0 0 0 560 
0 73 189 0 0 186 0 0 17 0 0 0 0 0 18 0 36 24 456 
0 73 124 0 0 111 0 0 0 10 0 0 0 0 18 0 0 0 664 
73 0 43 0 0 0 0 186 0 16 0 0 0 0 0 36 0 24 621 
73 0 311 0 117 0 0 0 132 0 0 0 0 0 18 36 0 0 313 
0 73 100 0 29 0 0 0 0 0 0 144 0 18 0 0 0 0 635 
0 73 9 0 0 0 93 0 0 0 0 102 0 0 18 36 0 0 668 
0 73 282 0 93 0 0 0 0 103 0 0 0 0 18 0 0 0 431 
73 0 66 0 30 0 0 0 0 0 0 146 0 0 18 0 0 24 644 
0 73 140 0 49 0 0 0 0 242 0 0 0 0 0 0 36 0 460 
0 73 4 71 0 0 0 0 0 0 0 78 0 16 0 0 0 24 732 
0 73 94 0 0 0 0 93 0 103 0 0 0 0 0 0 36 0 600 
0 73 23 0 0 0 0 49 0 0 0 240 0 0 0 0 0 0 616 
73 0 252 0 118 0 0 0 0 0 0 129 0 0 18 0 0 24 386 
73 0 46 0 0 40 0 0 0 197 0 0 0 0 18 36 0 48 542 
73 0 28 0 0 0 0 93 0 0 0 102 0 0 0 0 0 0 704 
0 73 29 0 0 0 0 30 0 0 0 0 149 0 0 0 0 48 671 
0 73 74 0 0 70 0 0 0 0 79 0 0 18 0 36 0 0 650 
73 0 4 0 0 0 118 0 0 0 0 129 0 18 0 0 36 24 598 
0 73 74 0 0 70 0 0 0 77 0 0 0 0 18 0 36 0 652 
100 0 120 0 0 104 0 0 118 0 0 0 0 0 0 50 0 33 474 
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5 
1 1 4 Mono- 
so- so- Am- so- 2 1 
dium dium 2 3 mo- dium 2 3 4 5 Argi- 3 Gly- 
Expt 1 4 Hydrox- Chlo- Citric Acetic nium Phos- 1 PEG PEG PEG PEG 2 3 nine Beta- cero1 Recipe Protein 
# MES HEPE ide ride Acid Acid Sulfate phate MPD 400 2K 4000 6K MgCI2 CaC12 HCI OG [75% 1 dis- dis- 
(Stock) [OSM] [0 5M] [2M] [2M] [2M] [2M] [2M] [2M] [30%] [30%] [30%] [30%] [30%] [0 2M] [0 2M] [0 5M] [0 5M] w/v] Water Total pensed pensed 
252 
253 
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255 
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265 
266 
267 
268 
269 
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281 
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2 84 
285 
286 
287 
288 
289 
290 
291 
292 
293 
100 0 11 0 0 0 116 0 0 0 0 10 0 0 0 0 0 67 696 
100 0 11 112 0 0 0 0 0 0 0 10 0 0 0 0 50 0 717 
100 0 119 0 0 103 0 0 0 114 0 0 0 0 0 50 0 0 514 
100 0 18 0 0 0 57 0 0 0 290 0 0 25 0 0 0 33 477 
100 0 5 0 0 0 112 0 0 0 0 0 10 0 0 0 50 0 723 
0 100 6 0 0 0 214 0 0 0 19 0 0 25 0 50 0 0 586 
100 0 5 73 0 0 0 0 0 81 0 0 0 0 25 50 0 67 599 
100 0 5 0 0 0 57 0 0 0 0 0 283 25 0 0 0 33 497 
100 0 14 0 0 0 0 44 0 219 0 0 0 0 0 0 0 67 657 
0 100 135 0 0 0 0 135 153 0 0 0 0 0 0 50 0 0 427 
100 0 11 0 0 0 114 0 0 10 0 0 0 0 0 0 50 33 681 
100 0 19 0 0 0 0 138 0 0 0 0 152 0 0 50 0 67 474 
100 0 11 0 0 0 112 0 0 0 0 10 0 25 0 0 50 0 692 
100 0 39 0 0 30 0 0 0 0 0 0 147 0 25 50 0 0 609 
0 100 12 114 0 0 0 0 10 0 0 0 0 0 25 50 0 33 655 
100 0 11 30 0 0 0 0 0 0 150 0 0 0 25 0 50 0 634 
0 100 91 0 0 72 0 0 82 0 0 0 0 0 0 0 50 33 572 
100 0 61 0 0 43 0 0 0 216 0 0 0 0 0 0 0 33 546 
100 0 140 0 56 0 0 0 0 0 0 278 0 0 0 0 50 0 375 
0 100 302 0 108 0 0 0 0 0 120 0 0 0 0 50 0 67 256 
100 0 5 43 0 0 0 0 0 216 0 0 0 0 25 0 50 33 527 
0 100 12 72 0 0 0 0 0 0 82 0 0 0 0 0 50 33 650 
100 0 40 0 0 0 0 135 0 0 0 148 0 0 0 50 0 0 527 
100 0 11 31 0 0 0 0 0 152 0 0 0 0 25 0 0 67 514 
100 0 14 0 0 0 0 57 0 0 0 0 285 0 0 50 0 67 426 
100 0 5 0 0 0 135 0 0 150 0 0 0 25 0 0 0 0 585 
100 0 18 0 0 0 43 0 0 216 0 0 0 0 25 0 50 33 514 
0 100 106 0 0 0 0 103 0 0 117 0 0 0 0 0 0 0 573 
100 0 11 0 0 0 71 0 0 0 80 0 0 0 25 50 0 0 663 
0 100 19 0 0 0 167 0 0 0 0 14 0 0 25 0 0 67 608 
100 0 65 0 0 57 0 0 0 0 290 0 0 0 0 50 0 33 405 
0 100 353 0 116 0 0 0 0 0 0 10 0 25 0 50 0 67 279 
0 100 170 0 0 165 0 0 0 0 15 0 0 0 0 50 0 33 466 
0 100 12 167 0 0 0 0 0 0 0 0 15 0 0 0 0 67 639 
100 0 18 0 0 0 0 114 0 0 10 0 0 0 0 0 0 33 724 
0 100 12 136 0 0 0 0 0 0 154 0 0 0 25 0 50 33 488 
0 100 19 0 0 0 71 0 0 78 0 0 0 25 0 0 50 0 657 
0 100 6 0 0 0 116 0 0 0 0 0 10 0 25 0 50 67 626 
100 0 9 0 0 0 0 214 19 0 0 0 0 0 0 0 0 0 658 
0 100 6 103 0 0 0 0 0 0 0 0 114 25 0 50 0 0 602 
100 0 5 0 0 0 57 0 0 286 0 0 0 0 25 50 0 67 410 
100 0 44 0 0 0 0 163 0 0 15 0 0 0 0 0 50 0 628 
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# MES HEPE ide ride Acid Acid Sulfate phate MPD 400 2K 4000 6K MgCI2 CaC12 HCI OG [75% 1 dis- dis- 
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3 24 
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330 
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332 
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335 
0 100 89 0 30 0 0 0 0 0 150 0 0 25 0 0 0 0 608 1000 
0 100 233 0 0 214 0 0 19 0 0 0 0 25 0 0 50 0 350 1000 
0 100 147 0 43 0 0 0 0 214 0 0 0 0 0 50 0 0 447 1000 
100 0 18 135 0 0 0 0 0 0 0 0 150 25 0 50 0 0 522 1000 
100 0 18 104 0 0 0 0 0 0 118 0 0 25 0 0 50 33 551 1000 
0 100 645 0 216 0 0 0 0 0 19 0 0 0 25 0 0 33 39 1000 
100 0 5 72 0 0 0 0 0 80 0 0 0 0 0 0 0 3 710 1000 
0 62 4 0 0 0 32 0 0 0 0 0 158 15 0 0 31 41 658 1000 
62 0 3 39 0 0 0 0 0 0 0 194 0 0 15 0 31 0 656 1000 
0 62 8 40 0 0 0 0 0 197 0 0 0 0 0 0 0 21 673 1000 
62 0 3 32 0 0 0 0 162 0 0 0 0 0 0 0 31 41 670 1000 
0 62 117 0 0 114 0 0 0 0 0 125 0 0 15 0 0 0 565 1000 
62 0 5 0 0 0 0 114 0 126 0 0 0 0 0 0 31 0 662 1000 
0 62 127 0 0 0 0 181 16 0 0 0 0 0 0 0 0 0 614 1000 
0 62 141 0 0 0 0 151 0 0 0 0 13 0 0 0 31 21 582 1000 
0 62 8 119 0 0 0 0 0 10 0 0 0 0 15 31 0 21 734 1000 
62 0 30 0 0 31 0 0 160 0 0 0 0 0 15 31 0 21 651 1000 
0 62 12 0 0 0 48 0 242 0 0 0 0 0 15 0 31 0 591 1000 
62 0 44 0 0 40 0 0 0 0 0 196 0 0 15 31 0 21 592 1000 
62 0 4 0 0 0 0 39 0 0 200 0 0 0 0 0 0 0 695 1000 
62 0 5 0 0 0 0 75 0 0 0 82 0 0 0 0 0 0 777 1000 
0 62 12 140 0 0 0 0 0 0 0 0 13 0 0 31 0 0 734 1000 
62 0 66 0 0 75 0 0 0 0 84 0 0 15 0 31 0 0 667 1000 
0 62 46 0 0 0 0 39 0 0 0 194 0 0 0 0 0 0 659 1000 
62 0 206 0 76 0 0 0 0 0 85 0 0 15 0 31 0 41 483 1000 
0 62 6 0 0 0 121 0 11 0 0 0 0 15 0 0 31 41 712 1000 
62 0 11 118 0 0 0 0 0 0 11 0 0 15 0 31 0 0 753 1000 
62 0 98 0 40 0 0 0 0 199 0 0 0 15 0 0 0 41 545 1000 
62 0 30 0 0 0 0 119 0 0 0 0 10 0 0 31 0 21 727 1000 
0 62 110 0 0 0 0 114 0 0 120 0 0 0 0 0 31 0 554 1000 
0 62 12 31 0 0 0 0 0 0 0 0 155 15 0 31 0 0 695 1000 
62 0 7 0 0 0 114 0 0 0 129 0 0 15 0 0 0 0 673 1000 
0 62 43 0 0 31 0 0 0 0 0 155 0 0 15 31 0 21 642 1000 
62 0 11 48 0 0 0 0 244 0 0 0 0 0 0 0 31 21 585 1000 
0 62 4 0 0 0 181 0 16 0 0 0 0 0 0 31 0 0 707 1000 
0 62 28 0 0 0 0 31 0 155 0 0 0 0 0 31 0 0 694 1000 
0 62 106 0 32 0 0 0 0 158 0 0 0 15 0 0 31 41 555 1000 
62 0 3 119 0 0 0 0 0 0 0 0 10 0 15 0 31 21 739 1000 
62 0 301 0 152 0 0 0 14 0 0 0 0 0 15 0 31 41 385 1000 
0 62 12 31 0 0 0 0 0 0 160 0 0 0 0 0 0 21 715 1000 
62 0 5 0 0 0 0 118 0 0 0 0 10 0 0 31 0 0 774 1000 
0 62 87 0 0 75 0 0 85 0 0 0 0 0 0 0 31 21 639 1000 
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3 62 
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3 74 
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62 0 116 0 0 116 0 0 0 0 0 127 0 0 15 0 31 41 492 
62 0 30 0 0 0 0 119 0 0 0 10 0 0 0 0 31 21 727 
0 62 74 0 0 0 0 183 0 0 15 0 0 0 0 0 31 41 593 
62 0 11 182 0 0 0 0 0 0 0 0 16 0 15 31 0 21 663 
0 62 39 0 0 32 0 0 0 0 0 0 158 0 15 0 31 41 622 
62 0 14 0 0 0 0 116 0 0 0 127 0 0 0 0 0 41 641 
0 62 189 0 0 182 0 0 0 0 0 16 0 0 0 0 0 21 531 
0 62 8 48 0 0 0 0 0 240 0 0 0 15 0 0 0 41 566 
62 0 9 0 0 0 0 40 0 199 0 0 0 0 0 0 31 41 618 
62 0 3 116 0 0 0 0 0 0 0 0 128 0 15 0 31 41 604 
62 0 68 0 0 75 0 0 0 0 0 84 0 0 15 0 31 41 624 
0 62 4 0 0 0 31 0 0 156 0 0 0 0 15 31 0 21 680 
0 62 22 0 0 0 0 48 0 0 0 237 0 0 0 31 0 21 581 
62 0 7 96 0 0 0 0 0 0 0 0 106 0 0 0 31 41 658 
0 62 168 0 0 0 0 182 15 0 0 0 0 0 0 0 31 21 521 
0 73 9 0 0 0 70 0 79 0 0 0 0 0 0 0 0 0 769 
73 0 120 0 0 148 0 0 0 0 0 13 0 0 0 36 0 0 602 
73 0 184 0 0 186 0 0 0 0 0 0 16 0 18 36 0 24 462 
73 0 296 0 149 0 0 0 0 0 0 13 0 0 18 0 36 24 391 
0 73 222 0 70 0 0 0 0 0 79 0 0 0 0 0 0 0 557 
0 73 109 0 0 85 0 0 0 105 0 0 0 18 0 0 0 48 551 
0 73 14 71 0 0 0 0 0 0 80 0 0 0 18 36 0 24 684 
73 0 86 0 39 0 0 0 0 0 0 0 193 0 18 0 0 0 591 
73 0 13 0 0 0 29 0 0 0 0 144 0 18 0 0 36 0 587 
0 73 158 0 0 149 0 0 0 0 13 0 0 18 0 0 0 24 564 
73 0 172 0 72 0 0 0 0 0 0 79 0 18 0 36 0 48 502 
73 0 205 0 95 0 0 0 0 0 0 0 105 18 0 0 0 48 456 
73 0 4 0 0 0 49 0 0 0 0 0 242 0 18 0 0 0 615 
0 73 71 0 0 0 0 94 0 104 0 0 0 0 0 0 36 24 597 
73 0 4 151 0 0 0 0 0 13 0 0 0 18 0 0 0 48 693 
0 73 86 0 0 72 0 0 0 0 0 79 0 0 0 36 0 48 606 
0 73 318 0 112 0 0 0 0 10 0 0 0 0 0 0 0 24 463 
0 73 446 0 149 0 0 0 0 13 0 0 0 0 16 0 0 24 277 
73 0 10 0 0 0 0 30 0 0 0 0 149 0 0 36 0 48 654 
0 73 4 0 0 0 185 0 0 0 0 16 0 0 18 0 0 0 704 
0 73 9 0 0 0 49 0 249 0 0 0 0 0 18 0 0 24 578 
0 73 34 0 0 30 0 0 0 0 0 0 149 0 0 0 36 48 630 
73 0 160 0 0 185 0 0 16 0 0 0 0 0 18 0 0 0 548 
0 73 189 0 0 186 0 0 0 16 0 0 0 0 0 0 0 24 511 
73 0 13 0 0 0 49 0 249 0 0 0 0 0 18 36 0 24 537 
0 73 4 0 0 0 95 0 0 0 0 0 105 0 0 0 0 48 574 
0 73 333 0 118 0 0 0 0 0 133 0 0 0 0 0 0 24 319 
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73 0 13 30 0 0 0 0 0 0 0 148 0 0 0 0 36 48 652 
73 0 4 0 0 0 72 0 0 0 0 0 79 18 0 0 0 48 706 
73 0 125 0 0 114 0 0 0 0 0 10 0 0 0 36 0 48 594 
0 73 58 0 0 49 0 0 247 0 0 0 0 0 0 36 0 0 538 
0 73 9 40 0 0 0 0 0 0 0 0 197 0 0 0 0 48 633 
0 73 32 0 0 0 0 72 0 0 0 79 0 0 0 0 0 48 697 
73 0 8 29 0 0 0 0 0 0 0 144 0 18 0 0 0 0 728 
73 0 4 49 0 0 0 0 0 246 0 0 0 0 0 0 36 48 544 
73 0 13 0 0 0 49 0 0 0 0 0 244 18 0 36 0 24 543 
0 73 14 0 0 0 49 0 0 246 0 0 0 18 0 0 0 48 552 
73 0 8 0 0 0 117 0 132 0 0 0 0 0 0 36 0 0 634 
73 0 4 0 0 0 39 0 200 0 0 0 0 18 0 0 36 24 606 
73 0 52 0 0 39 0 0 200 0 0 0 0 0 18 0 0 24 584 
73 0 98 0 39 0 0 0 0 0 200 0 0 18 0 0 36 24 512 
0 73 14 0 0 0 114 0 0 0 0 10 0 0 0 0 36 46 705 
0 73 53 0 0 39 0 0 0 0 198 0 0 0 0 0 0 0 638 
73 0 13 0 0 0 114 0 10 0 0 0 0 18 0 36 0 48 687 
73 0 8 0 0 0 49 0 0 0 0 242 0 0 0 0 0 24 604 
0 73 56 0 0 0 0 49 0 244 0 0 0 0 0 36 0 24 518 
73 0 8 0 0 0 94 0 0 0 107 0 0 0 18 0 0 24 676 
73 0 99 0 40 0 0 0 0 0 0 0 197 18 0 0 0 48 525 
0 73 14 114 0 0 0 0 10 0 0 0 0 0 0 0 36 48 705 
73 0 4 0 0 0 0 29 0 0 148 0 0 0 0 0 36 0 709 
100 0 18 0 0 0 115 0 0 10 0 0 0 25 0 0 0 67 664 
0 100 19 0 0 0 165 0 0 0 15 0 0 25 0 0 0 33 643 
0 100 421 0 135 0 0 0 153 0 0 0 0 0 25 0 0 0 166 
0 100 155 0 0 136 0 0 0 0 154 0 0 0 0 0 0 33 420 
100 0 94 0 0 104 0 0 0 0 0 0 115 0 25 50 0 33 478 
0 100 12 0 0 0 216 0 0 19 0 0 0 0 0 0 0 33 619 
100 0 80 0 30 0 0 0 153 0 0 0 0 0 25 0 50 33 529 
100 0 110 0 0 104 0 0 0 0 118 0 0 0 0 50 0 33 484 
0 100 19 72 0 0 0 0 0 0 0 79 0 0 25 0 50 33 621 
0 100 384 0 135 0 0 0 0 150 0 0 0 0 25 0 0 0 206 
0 100 122 0 0 116 0 0 0 0 0 0 10 0 25 0 0 67 560 
100 0 5 4 4  0 0 0 0 224 0 0 0 0 25 0 50 0 67 485 
0 100 179 0 0 167 0 0 0 0 15 0 0 25 0 0 50 67 397 
100 0 120 0 0 104 0 0 0 0 0 0 115 0 0 0 0 33 526 
0 100 56 0 0 44 0 0 224 0 0 0 0 0 25 0 50 67 434 
100 0 140 0 56 0 0 0 0 0 287 0 0 25 0 0 0 0 392 
100 0 5 0 0 0 214 0 19 0 0 0 0 0 25 0 0 0 637 
100 0 5 0 0 0 103 0 0 0 0 0 114 0 0 50 0 0 628 
100 0 11 0 0 0 135 0 0 0 153 0 0 0 25 50 0 0 526 
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0 100 88 0 0 0 0 114 0 10 0 0 0 0 0 0 0 33 654 
0 100 12 73 0 0 0 0 83 0 0 0 0 0 25 0 50 67 589 
100 0 67 0 30 0 0 0 0 0 0 146 0 0 0 0 50 0 607 
100 0 78 0 0 71 0 0 0 0 0 78 0 0 25 50 0 0 598 
0 100 6 153 0 0 0 0 0 0 0 14 0 0 25 50 0 0 642 
0 100 208 0 72 0 0 0 0 80 0 0 0 0 0 0 0 33 505 
100 0 9 0 0 0 0 214 0 19 0 0 0 0 0 0 0 0 658 
0 100 50 0 0 0 0 114 0 10 0 0 0 0 0 0 50 33 643 
0 100 19 30 0 0 0 0 0 0 0 0 147 0 0 50 0 0 654 
100 0 5 115 0 0 0 0 0 0 10 0 0 0 25 0 0 67 677 
0 100 75 0 0 57 0 0 0 0 290 0 0 0 0 0 50 33 394 
100 0 7 0 0 0 0 104 118 0 0 0 0 0 0 0 0 33 637 
100 0 18 0 0 0 73 0 0 0 83 0 0 0 25 50 0 67 584 
100 0 5 0 0 0 104 0 0 115 0 0 0 0 0 0 50 33 592 
100 0 11 135 0 0 0 0 0 0 0 148 0 25 0 50 0 0 530 
100 0 272 0 114 0 0 0 0 0 10 0 0 0 25 0 0 33 445 
100 0 5 0 0 0 43 0 218 0 0 0 0 25 0 0 50 0 559 
0 100 126 0 43 0 0 0 0 0 219 0 0 0 0 50 0 0 482 
100 0 54 0 0 57 0 0 0 256 0 0 0 0 0 0 0 67 436 
0 100 480 0 163 0 0 0 0 14 0 0 0 0 25 0 0 0 208 
100 0 18 0 0 0 214 0 0 0 19 0 0 0 0 0 50 0 599 
100 0 5 30 0 0 0 0 0 147 0 0 0 25 0 50 0 0 643 
100 0 18 103 0 0 0 0 116 0 0 0 0 0 25 0 50 0 588 
0 100 6 0 0 0 72 0 0 0 0 0 80 0 0 50 0 33 659 
0 100 19 103 0 0 0 0 0 0 117 0 0 0 0 50 0 0 611 
100 0 180 0 0 165 0 0 0 0 0 0 14 0 0 0 0 33 507 
100 0 11 116 0 0 0 0 10 0 0 0 0 25 0 0 0 67 671 
100 0 435 0 163 0 0 0 0 0 0 0 14 0 0 0 50 0 238 
0 100 12 214 0 0 0 0 0 0 19 0 0 0 25 0 50 0 579 
0 100 294 0 103 0 0 0 0 114 0 0 0 25 0 0 0 0 364 
0 100 6 138 0 0 0 0 0 0 0 151 0 0 0 0 50 67 488 
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We claim: 
1. Amethod for forming dyed protein crystals comprising: 
(a) providing a protein solution, wherein the protein 
solution contains at least one dye, which dye is capable 
of dyeing at least a portion of protein crystals formed 
from the protein solution; 
(b) subjecting the protein solution to environmental con- 
ditions effective to form protein crystals; and 
(c) detecting the presence of dyed protein crystals, 
whereby the presence of the dyed protein crystals 
indicates the presence of protein crystals. 
2. The method of claim 1, wherein the dye is selected from 
the group consisting of methylene blue, methylene green, 
Izit and crystal violet. 
3. The method of claim 1, wherein the dye binds to protein 
molecules of the protein crystals formed from the protein 
solution. 
4. The method of claim 1, wherein the dye does not bind 
to protein molecules of the protein crystals formed from the 
protein solution and wherein molecules of the dye reside in 
channels present in the protein crystals. 
5. The method of claim 1, wherein the protein solution is 
partitioned from the atmosphere. 
6. The method of claim 5, wherein the protein solution is 
overlayed with an oil selected from the group consisting of 
paraffin oil, silicone oil and combinations thereof. 
7. The method of claim 1, wherein the protein solution 
further comprises a component selected from the group 
consisting of salts, buffers, precipitants, crystallization aids 
and any combination thereof. 
8. The method of claim 7, wherein the component crys- 
tallizes under the environmental conditions of (b). 
9. The method of claim 8, wherein step (b) comprises 
addition of a precipitate solution. 
10. The method of claim 8, wherein the component 
crystals are undyed component crystals. 
11. The method of claim 8, further comprising detecting 
crystals formed in the provided protein solution and distin- 
guishing dyed protein crystals from undyed component 
crystals. 
12. The method of claim 11, wherein the protein crystals 
and the component crystals are detected by microscopy. 
13. A method for screening protein crystal growth con- 
ditions, comprising: 
(a) providing a set of at least two protein solutions, 
wherein the protein solutions contain a dye, which dye 
(i) is capable of dyeing at least a portion of protein 
crystals formed from the protein solution and (ii) does 
not dye a significant portion of component crystals 
formed from the protein solution; 
(b) subjecting the protein solutions to predetermined 
conditions, wherein the environmental conditions to 
which each member of the set of protein solutions is 
subjected is not identical to the environmental condi- 
tions to which another member of the set is subjected; 
and 
(c) detecting the presence or non-presence of dyed protein 
crystals andor undyed component crystals, wherein; (i) 
the presence of the dyed protein crystals indicates the 
formation of protein crystals; and (ii) the presence of 
undyed component crystals indicates formation of 
component crystals. 
14. The method of 13, wherein the set of protein solutions 
15. The method of 14, wherein the set of protein solutions 
consists of greater than 10 protein solutions. 
consists of greater than 100 protein solutions. 
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16. The method of claim 13, wherein the dye is selected 
from the group consisting of methylene blue, methylene 
green, Izit and crystal violet. 
17. The method of claim 13, wherein the protein solutions 
are partitioned from the atmosphere. 
18. The method of claim 17, wherein the protein solutions 
are overlayed with an oil selected from the group consisting 
of paraffin oil, silicone oil and combinations thereof. 
19. The method of claim 13, wherein the protein solution 
further comprises a component selected from the group 
consisting of salt, buffer, precipitant, crystallization aid and 
any combination thereof. 
20. The method of claim 13, wherein the component 
crystallizes under the environmental conditions of (b). 
21. The method of claim 20, wherein step (b) comprises 
addition of a precipitate solution. 
22. The method of claim 20, wherein the component 
crystals comprise undyed component crystals. 
23. The method of claim 22, further comprising distin- 
guishing dyed protein crystals from undyed component 
crystals. 
24. The method of claim 23, wherein dyed protein crystals 
are distinguished from component crystals by use of micros- 
COPY. 
25. The method of claim 13, wherein detection of dyed 
protein crystals indicates a combination of conditions to 
promote crystal growth of a protein in the provided protein 
solution. 
26. The method of claim 25, wherein the detected dyed 
protein crystals are evaluated in respect to protein crystal 
quality. 
27. The method of claim 26, wherein the evaluation of 
protein crystal quality includes criterion selected from the 
group consisting of size of crystals, volume of crystals, 
intensity of coloration of crystals by dye, color of coloration 
of crystals by dye, sharpness of crystal edges, crystal shape 
and combinations thereof. 
28. A method for forming dyed component crystals com- 
prising 
(a) providing a component solution, wherein the compo- 
nent solution contains at least one dye, which dye is 
capable of dyeing at least a portion of component 
crystals formed from the component solution; 
(b) subjecting the component solution to environmental 
conditions effective to form component crystals; and 
(c) detecting the presence of dyed component crystals, 
whereby the presence of the dyed component crystals 
indicates the presence of component crystals. 
29. The method of claim 28, wherein the component 
solution is partitioned from the atmosphere. 
30. The method of claim 29, wherein the component 
solution is overlayed with an oil selected from the group 
consisting of paraffin oil, silicone oil and combinations 
thereof. 
31. The method of claim 28, wherein the component 
solution further comprises a protein. 
32. The method of claim 31, wherein the protein crystal- 
lizes under the environmental conditions of (b). 
33. The method of claim 32, wherein step (b) comprises 
addition of a precipitate solution. 
34. The method of claim 32, wherein the protein crystals 
comprises undyed protein crystals. 
35. The method of claim 32, further comprising detecting 
any crystals formed in the provided component solution and 
distinguishing the undyed protein crystals from the dyed 
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component crystals on the basis that the component crystals 
are dyed component crystals and the protein crystals are 
undyed protein crystals. 
36. The method of claim 35, Wherein the Protein crystals 
and the Component crystals are detected by microscoPY. 
37. A method for screening protein crystal growth con- 
ditions, comprising: 
(a) providing a set of at least two protein solutions, 
wherein the protein solutions contain a dye, which dye 
crystal formed from the protein solution and (ii) does 
not dye a significant portion of protein crystals formed 
from the protein solution; 
(b) subjecting the protein solutions to predetermined 
conditions, wherein the environmental conditions to 15 
which each member of the set of protein solutions is 
subjected is not identical to the environmental condi- 
tions to which another member of the set is subjected; 
and predetermined program; 
(c) detecting the presence or non-presence of undyed 20 
protein crystals andor dyed component crystals, protein solutions; and 
wherein; 6)  the Presence of undyed Protein crystals 
indicates the formation of protein crystals; and (ii) the 
presence of dyed component crystals indicates forma- 
tion of component crystals. 
38. The method of 37, wherein the set of protein solutions 
consists of greater than 10 protein solutions. 
39. The method of 38, wherein the set of protein solutions 
consists of greater than 100 protein solutions. 
40. The method of claim 37, wherein the protein solution 30 
is partitioned from the atmosphere. 
41. The method of claim 40, wherein the protein solution 
is overlayed with an oil selected from the group consisting 
of paraffin oil, silicone oil and combinations thereof. 
further comprises a component selected from the group 
consisting of salt, buffer, precipitant, crystallization aid and 
any combination thereof. 
43. The method of claim 37, wherein the protein crystal- 
lizes under the environmental conditions of (b). 
44. The method of claim 43, wherein step (b) comprises 
addition of a precipitate solution. 
45. The method of claim 43, Wherein the Protein crystals 
comprise undyed protein crystals. 
46. The method of claim 45, further comprising distin- 45 
guishing the undyed protein crystals from the dyed compo- 
nent crystals. 
47. The method of claim 46, wherein the undyed protein 
crystal is distinguished from the component crystals by use 
of microscopy. 
48. The method of claim 37, wherein detection of the 
undyed protein crystals indicates a of condi- 
tions to promote crystal growth of a protein in the provided 
protein solutions. 
protein crystals are evaluated in respect to protein crystal 
50. The method of claim 49, wherein the evaluation of 
protein crystal quality includes criterion selected from the 
group consisting of size of crystals, volume of crystals, 
intensity of coloration of crystals by dye, color of coloration 
5 of crystals by dye, sharpness of crystal edges, crystal shape 
or thereof, 
51. An automated method of screening protein crystal 
growth conditions comprising the steps of 
(i) is capable of dyeing at least a portion of component 10 a) providing a set Of at least two protein 
wherein the protein solutions contain a dye, which dye 
(i) is capable of dyeing at least a portion of protein 
crystals formed from the protein solution and (ii) does 
not dye a significant portion of component crystals 
formed from the protein 
b) dispensing the Protein solutions Onto a Platform, 
wherein the protein solutions are dispensed using an 
automated dispensing system in accordance with a 
c) controlling the protein crystal growth conditions of the 
d) detecting the presence or non-presence of dyed protein 
crystals andor undyed component crystals, wherein the 
presence of the dyed protein crystals indicates the 
formation of protein crystals; and the presence of 
undyed component crystals indicates the formation of 
component crystals. 
52, The method according to claim 51 wherein protein 
53. A method for screening protein crystal growth con- 
a) Providing a set of at least two Protein solutions, 
wherein the protein solutions contain a dye, which dye 
6)  is capable of dyeing at least a Portion of component 
crystals formed from the protein solution and (ii) does 
not dye a significant portion of protein crystals formed 
from the protein solution; 
b) dispensing the protein solutions onto a platform, 
wherein the protein solutions are dispensed using an 
automated dispensing system in accordance with a 
predetermined program; 
c) controlling the protein crystal growth conditions of the 
protein solutions; and 
d) detecting the presence or non-presence of undyed 
protein crystals andor dyed component crystals, 
wherein the presence of the undyed protein crystals 
indicates the formation of protein crystals; and the 
presence of the dyed component crystals indicates 
54. The method according to claim 53 wherein the protein 
On the platform are Overlayed with an Oil. 
55. The method of claim 31, wherein the component 
25 
solutions on the platform are overlayed with an oil. 
ditions, 
42. The method of claim 37, wherein the protein solution 35 
40 
50 formation of component crystals. 
49. The method of claim 48, wherein the detected undyed 55 solution is Partitioned from the atmosphere. 
quality. * * * * *  
